The effect of air pollution on aggravation of neurodegenerative diseases: an analysis of long-term exposure to fine particulate matter and its components by Nunez, Yanelli
The effect of air pollution on aggravation of
neurodegenerative diseases: an analysis of
long-term exposure to fine particulate matter and
its components
Yanelli Nunez
Submitted in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy
under the Executive Committee







The effect of air pollution on aggravation of neurodegenerative diseases:
an analysis of long-term exposure to fine particulate matter and its
components
Yanelli Nunez
Background: Air pollution is one of the leading environmental issues in the world
today. In 2015, pollution-related diseases accounted for 16% of all deaths worldwide
— that is an estimated 9 million premature deaths were linked to air pollution. In
addition to the substantial effects on human health, air pollution-related diseases result
in productivity losses that reduce countries’ gross domestic product. Although air
pollution disproportionately affects middle- and low-income countries, it is still a major
issue in high-income countries, such as the United States, where 25% of Americans
breath air with pollutant levels above the national regulatory standards.
Fine particle matter (particles with diameter ≤ 2.5 μm, PM2.5) is the most ex-
tensively studied air pollutant and it has been causally linked with a wide range of
adverse health outcomes, including cardiovascular and pulmonary disease, myocardial
infarction, hypertension, congestive heart failure, arrhythmias, chronic obstructive pul-
monary disease, and lung cancer. Moreover, recent scientific evidence suggests that
PM2.5 affects the nervous system and possibly contributes to the development and ex-
acerbation of neurodegenerative diseases. This is increasingly relevant as populations
are aging and the number of adults living with neurodegenerative diseases increases,
negatively affecting families, communities, and health-care systems around the world.
Although millions of people suffer from neurodegenerative diseases, there is currently
no treatment that slows the progression of these conditions and no known cure or cause.
Thus, determining whether a link exists between air pollution and neurodegenerative
diseases is a goal of increasing importance.
Objective: The research presented in this dissertation has two main objectives: (1)
to characterize the relationship between long-term exposure to PM2.5 and disease aggra-
vation in two of the most prevalent neurodegenerative diseases worldwide: Alzheimer’s
(AD) and Parkinson’s disease (PD), as well as in the rare and devastating neurodegen-
erative motor disorder amyotrophic lateral sclerosis (ALS); (2) to identify the specific
PM2.5 chemical components that are associated with disease aggravation in PD.
Methods: We used data from the New York Department of Health Statewide
Planning and Research Cooperative System from 2000–2014 to identify patients’ first
hospitalization with a primary or secondary diagnosis of AD, PD, or ALS. With these
data, we constructed annual AD, PD, and ALS first hospitalization county counts (total
and sex- and age-stratified) for all of New York State (NYS). A patient’s first hospital
admission was used as a surrogate for disease aggravation, indicating the crossing point
into a more severe stage of the disease. We used prediction estimates from well-validated
models that incorporate satellite information and ground-based monitoring data to es-
timate annual PM2.5 and PM2.5 chemical component (nitrate, sulfate, organic matter,
sea salt, black carbon, and soil) concentrations across NYS at a high spatial resolution.
In Chapter 2, we used outcome-specific (AD, PD, or ALS) mixed quasi-Poisson models
with county-specific random intercepts to assess the relationship between long-term
exposure to PM2.5 and disease aggravation. In Chapter 3, we used a multi-pollutant
mixed quasi-Poisson model with county-specific random intercepts to identify specific
PM2.5 components associated with disease aggravation in PD. In all analyses, we eval-
uated potential nonlinear exposure–outcome relationships using penalized splines and
accounted for potential confounders.
Results: We observed a total of 264,075 AD, 114,514 PD, and 5,569 ALS first
admissions between 2000 and 2014. The hospitalization annual average counts per
county were 284, 131, and 6 for AD, PD, and ALS, respectively. In Chapter 2, we found
a nonlinear association between total PM2.5 exposure and PD hospitalizations, which
plateaued at higher concentrations of PM2.5 (> 13 μg/m
3, RR=1.08, 95% CI: 1.04–1.13
for a PM2.5 increase from 8 to 10 μg/m
3, Figure 2.3). We also found that patients with
a first PD hospitalization at age 70 or younger are at slightly higher risk for disease
aggravation at lower PM2.5 concentrations relative to those age >70. In the case of
AD, we observed evidence of a potential association between annual increases in PM2.5
exposure and disease aggravation, but only in a sensitivity analysis aiming to decrease
outcome misclassification. We found no association for ALS in the main analysis, but
we observed an unexpected negative association in those <70 years in the stratified
analysis. We found no evidence of effect modification by sex for any of the outcomes.
In Chapter 3, we observed a linear association between disease aggravation in PD and
long-term exposure to the PM2.5 components nitrate (RR = 1.05, 95%CI: 1.02–1.09 per
one standard deviation (SD) increase) and organic matter (RR = 1.05, 95%CI: 1.02–
1.07 per one SD increase), and a nonlinear association for black carbon with a negative
association above the 96th percentile of the BC concentration distribution (Figure 3.4).
We found no evidence of an association with sulfate, sea salt or soil.
Conclusion: Overall, our studies provide an analysis of the potential association
between long-term exposure to PM2.5, both as an overall pollution mixture and by chem-
ical composition, and disease aggravation in AD, PD, and ALS. Our findings suggest
that annual increases in county-level PM2.5 concentrations are associated with disease
aggravation in PD and possibly AD. We found that the PM2.5 components organic
matter and nitrate are particularly harmful in the association between PM2.5 and dis-
ease aggravation in PD. Additionally, our results indicate that current national PM2.5
standards may not be strict enough to safeguard the population’s neurological health.
Specifically, in Chapter 2, we observed that the PM2.5–PD association has a steeper
slope at lower concentrations that are well below the current annual National Ambient
Air Quality Standards for PM2.5. Thus, our findings warrant further investigation into
the potential link between long-term PM2.5 exposure and disease aggravation, particu-
larly in the context of PD. Our results also indicate that the chemical composition of
PM2.5 affects its neurotoxicity. Further research into how PM2.5 composition influences
the overall PM2.5 adverse effects is needed to fully understand the mechanisms that un-
derlie the association between exposure to PM2.5 and aggravation of neurodegenerative
diseases.
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Over Thanksgiving weekend in 1966, a large mass of stagnant air covered New
York City (NYC). For three days, the New York metropolitan area was engulfed in
dangerously high levels of nitrogen dioxide and carbon monoxide. The smog became so
severe that regional leaders issued an alert for residents and nearby industries to lower
emissions and health officials advised people with respiratory and hearth conditions to
stay home (NYT, 2017). The NYC 1966 smog event catalyzed national awareness of
air pollution as a serious health and environmental problem culminating in the 1967
Air Quality Act and the 1970 Clean Air Act (1970 CAA), representing the first federal
legislative actions aimed at controlling air pollution. Through the 1970 CAA, the federal
government for the first time conducted extensive ambient air monitoring studies and
stationary source inspections. Importantly, this legislation authorized the development
of comprehensive federal and state regulations to limit emissions from both stationary
and mobile sources. One of the primary goals of the 1970 CAA was to set National
Ambient Air Quality Standards (NAAQS) and require states to develop implementation
plans to achieve those standards (EPA, 2019b). NAAQS were established for five air
pollutants that became known as the criteria pollutants: carbon monoxide, lead (Pb),
nitrogen dioxide, ozone, sulfur dioxide, and particulate matter (EPA, 2016). As a result
of CAA monitoring and regulation programs, from 1970 to 2018, levels of the criteria
pollutants dropped from 7% to 86% on average nationally with the highest decreases in
Pb (-86%) and sulfur dioxide (-83%) and the smallest in ozone (-7%) and fine particulate
matter (-36%) concentrations (EPA, 2020a).
Although the quality of the air we breath has significantly improved since the en-
acting of the 1970 CAA, approximately 25% of Americans are still exposed to air
pollutants in concentrations that exceed the NAAQS — that is about 82 million people
in the United States (US) alone (EPA, 2020b). Furthermore, it is important to note
2
that current NAAQS are not necessarily proven to be safe for human health or the
environment. In fact, the law requires the Environmental Protection Agency (EPA)
to periodically review and update such standards — as new scientific evidence emerge
— to ensure that they provide adequate health and environmental protection (EPA,
2016).
Air pollution health effects
In 2015 alone, ambient air pollution was responsible for 4.2 million premature deaths
worldwide — the 4th leading cause of premature death globally (Cohen et al., 2017).
Air pollution has been linked to a wide range of diseases in several organ systems. Fine
particle matter is the most widely studied air pollutant and has been causally linked
with cardiovascular and pulmonary diseases, including myocardial infarction, hyperten-
sion, congestive heart failure, arrhythmias, chronic obstructive pulmonary disease, and
lung cancer — air pollution and particle matter are known group 1 human carcinogen
(Landrigan et al., 2018). Additionally, emerging evidence suggests air pollution may
have a causal link with neurodegenerative diseases in adults (Landrigan et al., 2018).
1.2 Air pollution and neurodegenerative diseases
Since 2000, numerous studies have examined the effects of exposure to low-to-
moderate air pollution levels in the the nervous system and reported potential effects
on neuroinflammation, oxidative stress, tau, amyloid and α-Synuclein proteinopathies
(Calderón-Garcidueñas et al., 2016, 2010, 2012; Calderon-Garciduenas et al., 2004;
Block and Calderón-Garcidueñas, 2009; Jang et al., 2018; Cheng et al., 2016; Costa
et al., 2014; Calderón-Garcidueñas et al., 2008) and systemic inflammation (Block and
Calderón-Garcidueñas, 2009; Genc et al., 2012; Calderón-Garcidueñas et al., 2008).
The latter has been highlighted as a plausible indirect biological mechanism by which
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air pollution can ultimately affect the central nervous system (CNS) and contribute to
neurodegenerative diseases (Feng et al., 2016; Block et al., 2007; Block and Calderón-
Garcidueñas, 2009). However, we still do not know with certainty if the observed
pathophysiological processes resulting from air pollution exposure contribute to the
development or exacerbation of neurodegenerative diseases.
The number of adults living with neurodegenerative diseases is increasing and neg-
atively affecting families, communities, and health-care systems around the world (He
et al., 2016; Savica et al., 2016; Nichols et al., 2019). Alzheimer’s (AD) and Parkin-
son’s (PD) diseases are the most prevalent neurodegenerative diseases worldwide, with
an estimated annual incidence rate of 1000–1200 and 26–86 cases per 100,000 people,
respectively (Lopez and Kuller, 2019; Hirsch et al., 2016; Lix et al., 2010; Niu et al.,
2017). Amyotrophic lateral sclerosis (ALS), although a rare disease, is the most com-
mon motor neuron disorder with an annual global incidence of 1–2.6 cases per 100,000
people (Talbott et al., 2016; Hirtz et al., 2007; Oskarsson et al., 2018).
Neurodegenerative diseases are characterized by progressive loss of neuronal func-
tion and ultimately cell death in the brain or peripheral nervous system. Each neu-
rodegenerative disease is characterized by the loss of a specific neuronal cell type which
subsequently manifests as motor or cognitive deficits or both. Although treatments
may help relieve some of the physical or mental symptoms associated with neurode-
generative diseases, there is currently no treatment that slows disease progression and
no known cure or cause of these diseases (Elbaz et al., 2016; Tysnes and Storstein,
2017; Yegambaram et al., 2015; Al-Chalabi and Hardiman, 2013). Only 5–10% of pa-
tients with neurodegenerative diseases have a familial history of disease, while the rest
are sporadic cases (Piaceri et al., 2013; Renton et al., 2014; Klein and Westenberger,
2012). Roughly 30–68% of the familial cases carry a genetic variant associated with
the disease and only 3-11% of the sporadic cases (Piaceri et al., 2013; Renton et al.,
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2014; Klein and Westenberger, 2012). Among the cases that share a common genetic
variant, there is variability in the clinical manifestation of disease, with varying rates
of disease progression and age on clinical disease onset — indicating a complex etiology
suggested to include environmental contributors (Al-Chalabi and Hardiman, 2013; Liu
et al., 2015b; Rana et al., 2019; Aivazidis et al., 2019; Al-Chalabi and Hardiman, 2013;
Chin-Chan et al., 2015). Although clinical symptoms of neurodegenerative diseases
generally appear in late adulthood, neuronal degeneration and other cellular patholo-
gies are known to begin years before clinical symptoms appear, rather than close to the
time of clinical diagnosis, (Van Zundert et al., 2012; Braak et al., 2004) which highlights
the importance of earlier life events and exposures.
To date, multiple environmental stressors have been hypothesized to contribute to
the etiology of AD, PD, and ALS, but none of these factors have yet been confirmed
as definite contributors. Calderon-Garciduenas et al. (2002) was the first study that
documented neuropathological processes resulting from air pollution exposure with rel-
evance to neurodegenerative pathology. The study described alterations in the nasal
respiratory and olfactory mucosae, the olfactory bulb (also identified as potential route
of air pollutant entry to the brain), and cortical and subcortical brain structures in
healthy dogs exposed daily to high levels of ambient air pollutants in Mexico city.
These alterations were not observed in canines from a comparable city, Tlaxcala, with
low levels of pollution. The observed alterations in the CNS included astrocyte activa-
tion, neuronal satellitosis, glial cell apoptosis, neuroinflammation, alterations of blood
brain barrier, nonneuritic plaques, and neurofibrillary tangles (Calderon-Garciduenas
et al., 2002). Ten years later, Calderón-Garcidueñas et al. (2012) reported similar find-
ings in post-mortem brain tissue of healthy young adults and children who lived in
highly polluted regions of Mexico city.
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1.3 Particulate matter
Air particulate matter pollution is a complex air-suspended mixture of solid and liq-
uid particulates that vary in size, shape, surface area, chemical composition, solubility,
and origin (Seinfeld and Pandis, 2016). Particulate matter is classified into categories
by its size, rather than chemical composition. The three major size categories based
on particulate aerodynamic diameter are: coarse (2.5 to 10 μm, PM10), fine (< 2.5
μm, PM2.5) and ultrafine (< 0.1 μm). Each size range has different formation mech-
anisms, composition, atmospheric lifetimes, spatial distribution and potential health
impacts—the smaller the particle, the higher its ability to traverse the alveolar region
of the respiratory system and pose a health risk (Wilson and Suh, 1997; Pope III and
Dockery, 2006). Despite their potential for health implications, ultrafine particulates
are currently not regulated or monitored by the EPA as a category, instead they are
encompassed within the PM2.5 category. In recent years, public health policy and re-
search has largely focused on PM2.5 which has emerged as a concerning threat to human
heath (Pope III and Dockery, 2006). Of relevance to the present dissertation, PM2.5 has
also most consistently been implicated in adverse neurological processes (Costa et al.,
2014).
PM2.5 as a mixture
The PM2.5 mixture is highly complex and dynamic, constantly changing over time
and space (Seinfeld and Pandis, 2016). In addition to pollution sources, geography and
climate also influence PM2.5 composition and concentration (Bell et al., 2007; Seinfeld
and Pandis, 2016; Van Donkelaar et al., 2019). PM2.5 can be both primarily emitted
and secondarily formed in the atmosphere. Primary particles are directly emitted from
sources, while secondary particles emerge through chemical process in the atmosphere
from precursor emissions such as sulfur dioxide, nitrogen oxides, volatile organic com-
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pounds, and ammonia in the presence of sunlight and heat (Pope III and Dockery,
2006). Numerous studies have linked exposure to the total PM2.5 mass concentrations,
and thus the overall PM2.5 mixture, with increased morbidity and mortality rates re-
lated to pulmonary and cardiovascular systems, as well as with systemic inflammation
(Andersen et al., 2012; Anderson et al., 2012; Wilker et al., 2015; Naghavi et al., 2017;
Yang et al., 2018; Liu et al., 2016; Xing et al., 2016; Atkinson et al., 2015). Recent stud-
ies also suggest a potential link between PM2.5 exposure and neurodegenerative diseases
(Liu et al., 2016; Fu et al., 2019; Shin et al., 2018; Seelen et al., 2017; Kioumourtzoglou
et al., 2015b; Weuve et al., 2012; Zanobetti et al., 2014), but a causal relationship
has not yet been established. In fact, the 2019 EPA Integrated Science Assessment
for PM2.5 categorized the effects of long-term and short-term PM2.5 exposure on the
nervous system as ”likely causal” and ”suggestive causal,” respectively, and stated that
there is a lack of supporting evidence for a causal relationship and results across studies
are contradictory (EPA, 2019a).
PM2.5 components
The PM2.5 mixture primarily consists of black carbon (BC), nitrate, sulfate, and
organic matter (OM) in terms of contribution to its mass concentration. Sea salt (SS)
and soil materials also contribute to the PM2.5 mass but to a lesser extend. Other
materials, including metals, are also present in the mixture but in trace amounts. The
percent mass that each component contributes to the total PM2.5 mass concentration
varies both regionally and temporally (Seinfeld and Pandis, 2016; Van Donkelaar et al.,
2019). However, the adverse neurodegenerative effects of PM2.5 have largely been eval-
uated solely based on particulate size without considering the chemical composition of
the mixture. As a result, the PM2.5 composition or components that are mostly linked
to neurodegeneration are largely unknown.
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BC is a primary component of PM2.5 derived from combustion processes and char-
acterized by its light absorbing qualities. Major BC sources include gasoline or diesel
vehicle emissions and wood and coal burning for power generation. BC is generally con-
sidered a traffic-related pollutant, especially in urban environments, and is often used
as a surrogate for traffic pollution. It has been extensively studied in epidemiological
studies and evidence supports a causal effect of BC in lung cancer, cardiovascular mor-
tality and morbidity, adverse birth outcomes, and nervous system effects, particularly
with outcomes related to cognition in both older adults and children (Grahame et al.,
2014; WHO, 2012; Chiu et al., 2013; Huang et al., 2013; Power et al., 2011; Suglia et al.,
2007; Wurth et al., 2018). The association of BC with neurodegenerative diseases has
been evaluated previously only in one epidemiological study that found no association
between exposure and risk for PD (Toro et al., 2019). However, two other studies have
linked exposure to other traffic-related pollutants (nitrate oxide and carbon monoxide)
with risk of PD (Ritz et al., 2016; Lee et al., 2016).
Nitrate and Sulfate are largely secondary PM2.5 components that exist in the
form of ammonium nitrate and ammonium sulfate particles, respectively (for simplicity,
these will be referred to as nitrate and sulfate). The principal sources of sulfur oxide
in the US include fuel combustion from electric utilities and industrial activities (Reiss
et al., 2007). In large urban centers in the Northeaster US, like NYC and Boston,
the use of heavy oils No. 4 and No. 6 for space heating has also been a significant
contributor of sulfur oxide (Kheirbek et al., 2017). In NYC, however, due to a the
heavy oil phaseout process that began in 2015, heating-related sulfur emissions have
decreased (nyccleanheat, 2015). In the case of nitrate oxides, emissions are largely
from power plants, industrial fuel combustion, and motor vehicles (Reiss et al., 2007).
Agriculture and livestock farming are the major sources of ammonia globally; however,
ammonia is also a byproduct of fossil fuel combustion and emission analyses suggest
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that traffic may be the most significant source of ammonia in urban sites (Sun et al.,
2014; Shon et al., 2012). Sulfate exposure has been associated with cardiovascular
and respiratory mortality and hospitalization (Pope III et al., 2007; Lepeule et al.,
2012; Schwartz et al., 1996; Chen et al., 2018; Jones et al., 2015; Brook et al., 2007;
Ito et al., 2011; Gwynn et al., 2000; Atkinson et al., 2015), but its association with
neurodegenerative outcomes has not yet been examined. Information about the health
implications of nitrate exposure is generally more limited, but three studies have linked
nitrate exposure with all-cause mortality (Ostro et al., 2007; Cao et al., 2012; Hoek
et al., 2000) and one study suggested a link with cardiovascular and respiratory related
mortality (Cao et al., 2012). No study has evaluated the potential nitrate contribution
to neurodegenerative diseases.
The OM component of PM2.5 is complex and includes both primary and secondary
particles. OM encompasses hundreds of compounds such as organic carbon, polycyclic
aromatic hydrocarbons (PAH), alkanes, and fatty acids (Jacobson et al., 2000), but
the wide variety of organic compounds present in PM2.5 remains largely uncharacter-
ized (Jacobson et al., 2000). OM is a major contributor to the total PM2.5 mass in
the Northeastern US (Seinfeld and Pandis, 2016; Saunders and Waugh, 2015), where
its primary source is from residential and industrial biofuel emissions (Saunders and
Waugh, 2015). Various OM compounds have well-known toxicities. For instance, PAHs
are known carcinogens and immunosuppressants; PAH exposure has also been associ-
ated with neurodevelopmental disturbances in children, inflammatory responses in vitro
and in animal studies, and degenerative-disease-like syndromes in zebra fish (Peterson
et al., 2015; Den Hartigh et al., 2010; Gao et al., 2015). The OM PM2.5 has also been
associated with increased rates of hospital admissions for cardiovascular disease and
all-cause mortality (Cao et al., 2012; Atkinson et al., 2015; Kioumourtzoglou et al.,
2013). Despite the known neurotoxicity of various OM compounds, the association of
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OM PM2.5 with neurodegenerative diseases has not yet been examined.
Although metals make up 1 to 2% of PM2.5 total mass (Liu et al., 2015a; Pekney
et al., 2006), their contribution to the observed PM2.5 adverse health effects is likely
substantial. Similarly to OM, the metal portion of PM2.5 consists of various metals,
including copper, chromium, iron, nickel, lead, zinc, vanadium, arsenic, cadmium, man-
ganese, and others. Major sources of metal PM2.5 are the steel production industry,
waste incinerators, coal combustion, crustal materials, battery manufacturing plants,
power plants, blast furnaces, and also traffic and road dust (Pekney et al., 2006). Some
metals found in the PM2.5 mixture mass are well-known neurotoxicants. Manganese
(Mn) exposure, for instance, has extensively been linked with neurodegenerative patho-
logical processes in vivo and in vitro (Dorman, 2017; Guilarte et al., 2008; Chen et al.,
2002). In humans, exposure to high levels of Mn (via inhalation) results in a PD-like
syndrome characterized by impaired fine motor control, muscle weakness and psychi-
atric symptoms (Guilarte, 2011; Smith et al., 2017; Racette, 2014), and moderate Mn
and Cu aerosol exposures are suggested to advance the age of PD clinical diagnosis
and increase its incidence (Finkelstein and Jerrett, 2007; Willis et al., 2010). Together,
these data suggest that there is a potentially strong contribution of metal components
to PM2.5 neurotoxicity.
Soil and SS accounted for a small fraction of the total PM mass in the Northeastern
US (Van Donkelaar et al., 2019). SS includes sodium and chloride ions from onshore
winds. Soil matter includes crustal-associated materials, such as silicon, calcium, potas-
sium and aluminum; soil particles can also be produced mechanicaly (e.g. agriculture,
mining, construction, and road traffic) or through combustion processes (e.g. wild
fires or biomass). Studies evaluating potential adverse health effects of exposure to
the SS and soil PM2.5 components have found no associations or negative associations
(Kioumourtzoglou et al., 2015a; Schlesinger, 2007). Therefore, these components are
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not likely major contributing factors to PM2.5 neurotoxicity.
Currently, results across studies evaluating the potential contribution of PM2.5 ex-
posure to neurodegerative diseases present unexplained differences. Given the dynamic
composition of PM2.5 across time and space, it is a possibility that such differences
might partially be due to variations in the PM2.5 chemical composition. However,
the number of studies characterizing the relationship between PM2.5 components and
common neurodegenerative disease remains limited.
1.4 Dissertation overview
Diseases of the CNS are an emerging focus of air pollution health studies, but the
association between exposure and disease is not yet fully characterized and the burden
of disease not yet quantified. To fill this knowledge gap, the research work presented
in this dissertation examines the association between long-term exposure to currently
acceptable levels, i.e., below the current NAAQS, of the criteria pollutant PM2.5 and
clinical aggravation of neurodegenerative diseases.
In Chapter 2, we evaluated the relationship between long-term PM2.5 exposure and
disease aggravation in two of the most prevalent neurodegenerative diseases worldwide,
AD and PD, and the neurodegenerative motor-neuron disorder ALS. The aim of this
study was to contribute to the body of knowledge regarding this potential link by
bringing novel insight from a diverse geographical region and population that includes
both rural and urban sites — NYS. We quantified the cumulative effect of one-year
exposure to low-to-moderate levels of PM2.5 on clinical aggravation of AD, PD, and
ALS. The levels of exposure we investigated were for the most part at or under the
NAAQS, and are thus considered safe under current US standards. We leveraged
hospitalization data from the New York Department of Health Statewide Planning and
Research Cooperative System (SPARCS) from 2000–2014, which includes 98% of all
11
hospitalizations in non-federal acute care facilities across New York State (NYS), and
a well-validated air pollution prediction model that incorporates satellite information
and ground-based monitoring data to estimate PM2.5 concentrations (Van Donkelaar
et al., 2019).
Building on the positive results obtained in Chapter 2 for PD, in Chapter 3 we
further characterized the relationship between PM2.5 and clinical aggravation of PD.
Given that exposure to PM2.5 encompasses exposure to multiple chemical compounds,
in this Chapter we further dissected our examination by evaluating six PM2.5 com-
ponents and their specific association with clinical aggravation of PD. Specifically, we
analyzed nitrate, sulfate, OM, BC, SS and soil, which account for most of the total
PM2.5 mass concentration in NYS. The aim of this study was to identify PM2.5 com-
ponents that are particularly harmul for disease aggravation in PD. These findings are
an important step to elucidate potential mechanisms by which PM2.5 exerts its adverse
effects on neurodegenerative diseases. Additionally, information on PM2.5 components
can be used to identify specific pollution sources for targeted interventions. In this
study, we used PD hospitalization data from SPARCS 2000–2014 and exposure data
from component-specific air pollution models that combine satellite remote sensing,
chemical transport modeling, and ground-based monitor information to estimate the
concentrations of PM2.5 components (Van Donkelaar et al., 2019).
Finally, as an Appendix, we included a laboratory-based exploratory study which
examined the effects of long-term exposure to Mn via drinking water on motor function,
memory, and other behaviors in an ALS mouse model. We used a knock-in mouse model
carrying an incompletely penetrant genetic variant associated with ALS to evaluate the
potentially differential effects of Mn exposure based on genetic susceptibilities. This
work supplements our epidemiological studies by evaluating an important component
of PM2.5 the metal Mn, for which we had no available data to assess in the population
12
level.
In summary, the work presented in this dissertation aims to contribute to the ex-
amination of the possible causal association between long-term exposure to PM2.5 and
clinical aggravation of neurodegenerative diseases. Because the health effects of PM2.5
may vary by composition, we examined the specific effects of PM2.5 components in
addition to the effect of the total PM2.5 mixture. With the presented work, we hope
to contribute to a better understanding of the widespread health effects of air pollu-
tion and ultimately inform the development and enforcement of protective actions and
regulations aimed at improving air quality.
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2.1 Abstract
Background: Environmental risk factors for neurodegenerative diseases, an increas-
ing global issue, are largely unknown. A growing body of evidence suggests that air
pollution may contribute to these conditions.
Methods: We used data from the New York Department of Health Statewide Plan-
ning and Research Cooperative System (2000–2014) to examine the association between
fine particulate matter (PM2.5) exposure and disease aggravation in amyotrophic lateral
sclerosis (ALS), Alzheimer’s (AD), and Parkinson’s (PD) diseases, using first hospital-
ization as a proxy for disease aggravation. We used annual PM2.5 predictions from a
well-validated model and constructed annual AD, PD, and ALS first hospitalization
county counts (total and sex- and age-stratified). We used outcome-specific mixed
quasi-Poisson models with county-specific random intercepts. We allowed for nonlin-
ear exposure–outcome relationships using penalized splines and accounted for potential
confounders.
Results: We observed a total of 264,075 AD, 114,514 PD, and 5,569 ALS first admis-
sions. The hospitalization annual average counts per county were 284, 131, and 6 for
AD, PD, and ALS, respectively. We observed a significant non-linear PM2.5–PD asso-
ciation with a steeper slope at lower concentrations (RR=1.08, 95% CI: 1.04–1.13 for
a PM2.5 increase from 8 to 10 μg/m
3) but no association for AD or ALS. We observed
effect modification by age for ALS and, at lower concentrations, for PD with a positive
association in those <70. For ALS, we observed a negative association in those <70
years. We found no evidence of effect modification by sex for any of the outcomes.
Conclusion: Our findings suggest that annual increase in county-level PM2.5 concen-
trations may contribute to aggravation of PD and, in certain age subgroups, ALS.
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2.2 Introduction
As the world population continues to grow older and the proportion of elderly
increases, neurodegenerative diseases are projected to rise (He et al., 2016; Savica et al.,
2016). AD and PD are the most prevalent neurodegenerative diseases worldwide, with
an estimated annual incidence rate of 1000–1200 and 26.2–85.9 cases per 100,000 people,
respectively (Lopez and Kuller, 2019; Hirsch et al., 2016; Lix et al., 2010; Niu et al.,
2017). ALS, is a rare motor neuron disorder with an annual global incidence of 1–2.6
cases per 100,000 people (Talbott et al., 2016; Hirtz et al., 2007). The etiology of these
diseases is largely unclear, but research indicates contributions by both genetic and
environmental factors (Al-Chalabi and Hardiman, 2013; Chin-Chan et al., 2015).
AD, PD, and ALS have considerable variability in the rate of clinical aggravation
even in patients who share the same genetic variant(s) (Schrag et al., 2007; Wang
et al., 2015; Paez-Colasante et al., 2015; Poewe and Wenning, 1998; Poewe, 2006).
However, much is yet to be understood about factors influencing this process and par-
ticularly about the potential environmental contributors (Elbaz et al., 2016; Tysnes and
Storstein, 2017; Yegambaram et al., 2015; Al-Chalabi and Hardiman, 2013). Environ-
mental exposures may exacerbate the neurodegenerative process accounting for some
of the observed variability in the clinical progression of the disease (Al-Chalabi and
Hardiman, 2013; Liu et al., 2015; Rana et al., 2019; Aivazidis et al., 2019). Thus, iden-
tification of modifiable environmental factors that contribute to neurodegeneration can
lead to development of preventive strategies to minimize the rate of disease aggravation
by reducing high-risk exposures.
A growing body of evidence suggests that air pollution exposure can negatively im-
pact the central nervous system (CNS). Toxicological studies have linked exposure to
particles with diameter ≤ 2.5 μm (PM2.5) with pathophysiological processes including
neuroinflammation, oxidative stress, and tau, amyloid and α-Synuclein proteinopathies
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(Calderón-Garcidueñas et al., 2016, 2010, 2012; Calderon-Garciduenas et al., 2004;
Block and Calderón-Garcidueñas, 2009; Jang et al., 2018; Cheng et al., 2016; Costa
et al., 2014; Calderón-Garcidueñas et al., 2008) PM2.5 exposure has also been con-
sistently associated with systemic inflammation, in turn linked to neuroinflammation
(Block and Calderón-Garcidueñas, 2009; Genc et al., 2012; Calderón-Garcidueñas et al.,
2008), which has been highlighted as a plausible biological mechanism by which PM2.5
can ultimately affect the CNS (Feng et al., 2016; Block et al., 2007; Block and Calderón-
Garcidueñas, 2009). Epidemiological studies have identified long-term particle exposure
as a risk factor for AD and PD (Liu et al., 2016; Fu et al., 2019; Shin et al., 2018) and
accelerated disease progression(Kioumourtzoglou et al., 2015). However, the latter was
limited only to Medicare beneficiaries (≥65 years old) and urban centers in the north-
eastern US. To date, only one epidemiological study, based on a Netherlands cohort,
has evaluated the relationship between long-term exposure to PM2.5 and risk of devel-
oping ALS (Seelen et al., 2017) finding an association, but the contribution of PM2.5
exposure to disease exacerbation has not yet been studied in ALS.
Here, we evaluated the potential contribution of long-term PM2.5 exposure to AD,
PD and ALS clinical disease aggravation using first hospitalization data as a surrogate.
Specifically, we examined whether yearly fluctuations in county-wide PM2.5 concen-
trations in all of New York state (NYS) from 2000–2014 were associated with first
hospitalization rates in each outcome. We hypothesize that if PM2.5 exposure exacer-
bates the disease, then first hospitalizations will occur at higher rates for the years with
higher PM2.5 concentrations. To identify potential sensitive groups, we examined sex
and age as potential modifiers. Our study extended beyond previous studies by using
a more diverse population that includes both rural and urban residents, as well as a




We obtained patient data from the New York Department of Health Statewide
Planning and Research Cooperative System (SPARCS), a comprehensive data reporting
system that collects information on hospital admissions and emergency department
(ED) visits within NYS. SPARCS data include information on approximately 98% of
all hospitalizations in non-federal acute care facilities, regardless of insurance status.
The dataset also contains demographic data including age, sex, and patient residential
address. At the first hospitalization, a unique ID is assigned to the patient allowing for
tracking over time. We used SPARCS data on first hospitalizations and ED visits for
AD, PD and ALS from 2000 to 2014. Columbia University Institutional Review Board
approval was obtained to conduct the analysis. The same board waived the need for
informed consent because of the public nature of the data.
Outcome Definition
We extracted all hospitalizations and ED visits with International Classification of
Diseases ninth revision (ICD-9) codes 331.0, 332.0, and 335.20 for AD, PD, and ALS, re-
spectively. Each code is unique to each disease. We used both primary and secondary
discharge codes to identify patients with each of these conditions and restricted our
analyses to first hospitalizations. Primary diagnoses capture health complications di-
rectly related to these outcomes (e.g., motor complications or cognitive and psychiatric
impairments), whereas secondary diagnoses capture health complications indirectly re-
lated to these outcomes (e.g., falls, infections) 2.1. By focusing on incidence of first
hospitalization using both primary and secondary diagnoses, we are evaluating whether
PM2.5 exposure is associated with cases developing — for the first time — clinical symp-
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toms severe enough to require hospitalization. Our outcome definition, thus, captures
the clinical crossing point to a more severe stage of the disease, a proxy for disease
exacerbation. We used SPACRS data between 1995–1999 to identify potentially preva-
lent cases and excluded any subjects with a primary or secondary diagnoses prior to
2000 from our analyses.
Air Pollution Data
Annual PM2.5 concentrations were predicted by a well-validated air pollution pre-
diction model (Van Donkelaar et al., 2019). Briefly, this model relates a combined
total-column aerosol optical depth from multiple sources, primarily satellite retrievals,
to near-surface PM2.5 using the spatio-temporally varying geophysical relationship pre-
dicted by a chemical transport model. Ground-based monitors were then incorporated
using a geographically weighted regression. This model performs well, with cross vali-
dated R2=0.76. We estimated annual PM2.5 concentrations for each county by averaging
the predicted annual PM2.5 over all grids within a county. We assigned exposures based
on patients’ county of residence and year of first hospitalization.
Potential Confounders
For all analyses, we used aggregated counts of hospital data per county and year for
each outcome. In this design, the unit of analysis is county-year; therefore, potential
confounders can only be variables that vary from year to year and across counties,
and co-vary both with the outcome (hospital admission counts) and the exposure.
Individual-level variables, thus, cannot act as confounders.
To account for potential spatial confounding, we included county-specific socioeco-
nomic status (SES) variables obtained from the US Census Bureau and the American
Community Survey for the years 2000, 2004–2014. Data included median household
29
income, percent of residents below poverty, percent of residents without high school
degree, and racial/ethnic distribution (White, Asian, African American and Hispanic).
We also included county-level smoking prevalence and percent obesity data, obtained
from the Behavioral Risk Factor Surveillance System. For the above variables, we in-
terpolated years without available data (2001–2003) using a generalized additive model
with a penalized spline for year to allow for nonlinear time trends.
To account for potential temporal confounding, we adjusted for long-term trends
using calendar year and summer and winter mean temperatures. We retrieved daily
mean temperatures at a 1/8th-degree grid from the North America Land Data Assim-
ilation System (Mitchell et al., 2004). We calculated monthly mean temperatures at
the county level from daily temperatures over all grids within a county, then averaged
June–August and December–February estimates to obtain the summer and winter mean
temperature, respectively, for each year.
Statistical Analysis
We ran separate models for each outcome of interest — PD, AD, and ALS — to
assess whether year-to-year fluctuations in county-wide PM2.5 concentrations are asso-
ciated with annual rates of first hospitalization. Using SPARCS data from 1995–1999,
we identified patients with first admissions that occurred prior to 2000 and removed
from analysis, thus effectively removing potentially prevalent cases. We used a variant
of the difference-in-differences causal approach(Wang et al., 2016). The association
was estimated using outcome-specific generalized additive mixed models to allow for
nonlinear exposure–outcome relationships and the inclusion of both fixed and random
effects. Specifically, we used quasi-Poisson regression models, allowing for potential
overdispersion in the outcomes. We used county-specific random intercepts to account
for within-county clustering and allow shared information across counties, and included
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county population size as the offset term in the models.
We followed a rigorous process to avoid any potential misspecification in the health
outcome models. We first included all terms (exposure and potential confounders)
linearly in the models. Then, we used penalized splines for all continuous covariates
to allow for any potential non-linear confounding. Once we identified the nonlinear
confounders, we included a penalized spline for PM2.5 to comprehensively characterize
the exposure–response relationship. If no deviations from linearity were detected, we
included linear terms in the final model. For all penalized splines, we used generalized
cross-validation and the Akaike information criterion to detect nonlinearities and select
the optimal degrees of freedom for each variable in each outcome model.
All results are presented as rate ratios (RR) per 1 μg/m3 increase in annual PM2.5
and 95% confidence intervals (CI), if linear. If non-linear exposure–response curves
were detected, we present the entire curve and the corresponding confidence bands. All
analyses were performed using the R Statistical Software version 3.6.1 (Foundation for
Statistical Computing, Vienna, Austria).
Effect Modification
To assess potential effect modification by sex and age, we ran sex- and age-stratified
analyses. Age data included patients as young as 30 years for PD and AD and 15 years
for ALS. The age categories we used for the stratified analysis were: <70, and ≥70.
Following the workflow described for the main analysis, we developed a health model
for each subpopulation (two age models and two sex models) for each of the outcomes.
The stratified health models also included the same covariates as in the main analysis,
but with subpopulation-specific offsets. We evaluated evidence of effect modification
by examining overlapping confidence intervals.
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Sensitivity Analysis
To assess the robustness of our findings, we conducted a sensitivity analysis to eval-
uate medical diagnosis accuracy in each outcome and reduce the possibility of false
positives influencing our results. To build the models, we followed the same steps as
in the main analysis, but only included patients with at least two medical hospital-
izations with a primary or secondary discharge code for each of the outcomes. The
disease diagnosis in the second hospitalization served to confirm the diagnosis in the
first hospitalization, but cases were counted only in the year of the first hospitalization.
2.4 Results
Study Population Characteristics
We included data from all 62 NYS counties. The average number of subjects for each
outcome per county-year, along with covariate descriptive statistics, are presented in
Table 2.1. We observed 264,075 AD, 114,514 PD, and 5,569 ALS first admissions (either
as primary or secondary diagnoses) over the 15-year period. Of the total PD and AD
hospitalizations, 8.6% and 11.35% had a primary diagnosis of PD and AD, respectively.
16.52% of AD and 15.35% of PD patients had a hospitalization with a primary diagnosis
within the Diseases of the Circulatory System category (e.g. cardiovascular diseases),
which was the most common primary diagnoses category. In the case of ALS, 40%
of all hospitalizations had a primary diagnosis of ALS, which was the most common
primary diagnosis among ALS patients. The second most common primary diagnoses
for ALS patients were within the Diseases of the Respiratory System category (14.80%)
(Figure 2.1). Of the total cases, 60.7% were females and 87.6% were ≥ 70 years old
(Supplemental Table 2.2). Across counties, the mean age (standard deviation, SD) at
first hospitalization was 82 (0.7), 76 (1.0), and 65 (3.2) years for AD, PD, and ALS,
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respectively. The average PM2.5 concentration was 8.0 μg/m
3 (2.3); interquartile range,
IQR=2.7 μg/m3).
Exposure–Response Relationship
In the main analysis, the exposure–response association deviated from linearity in
PD and AD. We found statistically significant effect estimates for PM2.5 concentrations
only for PD with stronger near-linear estimates at lower concentrations, e.g., RR for
going from 8 to 10 /mugm/ in PM2.5 was 1.08 (95% CI: 1.04–1.13), and a relative
plateauing of the association above approximately 11 μg/m3 (Figure 2.3). For ALS we
observed a linear positive association that did not reach significance (RR=1.02, 95%
CI: 0.98–1.05).
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Table 2.1: Descriptive statistics based on per county per year estimates from 2000–2014
in NYS.
Mean St Dev 25% Median 75%
Outcome
AD 283.9 469.1 45.0 82.0 260.0
Female 191.0 319.0 29.0 53.0 173.0
Male 93.6 151.0 16.0 30.0 87.7
<70 years 19.9 35.5 3.0 6.0 17.0
≥70 years 265.0 436.0 42.0 76.0 244.7
PD 131.1 222.0 21.0 37.0 121.0
Female 57.8 98.8 9.0 16.0 52.0
Male 65.4 110.0 11.0 19.0 60.0
<70 years 29.0 51.6 4.0 9.0 26.0
≥70 years 94.9 160.0 15.0 26.0 86.0
ALS 6.0 9.5 1.0 2.0 6.0
Female 2.7 4.5 0.0 1.0 3.0
Male 3.3 5.3 0.0 1.0 3.0
<70 years 4.2 6.49 1.0 2.0 4.0
≥70 years 2.9 3.9 1.0 1.0 3.0
Exposure
PM2.5 (μg/m
3) 8.1 2.3 6.4 7.6 9.2
Covariates
Median income (×$1000) 49.1 12.6 41.3 45.7 52.4
Percent below poverty 12.9 4.1 10.4 12.6 14.9
Percent w/o high school 18.1 7.3 12.8 17.3 22.2
Percent smoking prevalence 22.9 3.9 20.7 23.6 26.1
Percent obesity 25.0 4.5 22.3 25.4 27.8
Percent Hispanic 6.5 8.6 1.9 2.9 6.2
Percent White no Hispanic 83.6 16.8 80.3 90.2 94.0
Percent Black no Hispanic 5.7 6.3 1.4 3.4 7.5
Percent Asian no Hispanic 2.2 3.4 0.5 0.9 2.2
Summer mean temp. (oC) 20.2 1.5 19.2 20.2 21.1
Winter mean temp. (oC) -3.1 2.5 -4.9 -3.3 -1.5
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Figure 2.1: Percent of primary diagnosis across categories. The x-axis shows
the diagnosis categories and the y-axis the percentage of primary diagnosis within that
category. The blue bar corresponds to the outcome (AD, PD, ALS).
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Figure 2.2: Effect estimates for the association between annual PM2.5 expo-
sure and ALS first hospitalization. Association is based on evaluation of exposure
over a 15-years period in a per county analysis in NYS. The x-axis of the plot shows
the strata and the y-axis the RR per 1.0 μg/m3 increase in county-wide PM2.5 concen-
tration. Error bars indicate the 95% CI.
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Figure 2.3: Association between annual PM2.5 exposure and first hospitaliza-
tion for AD (top) and PD (bottom). The solid black lines indicate the exposure–
response curves, as rate ratios relative to the mean PM2.5 concentration (8.0 μg/m
3),
and the gray shaded areas are the 95% confidence bands — both correspond to the




For AD, we found no evidence of differential effects by age or sex. In both males and
females, the association with PM2.5 exposure remained nonlinear and not significant.
For age, we observed a significant nonlinear association in the <70 age group but not
in the ≥70 group. However, these differences between age groups were not significant
as evidenced by the overlapping CIs (Figure 2.4).
In the case of PD, there was insufficient evidence for effect modification by sex.
There was some evidence for modification by age at levels below 10 μg/m3, with higher
estimates among those <70 years old, but at higher concentrations — where we have
a small number of observations — the confidence intervals overlapped. In the <70
age group, we found a positive monotonically increasing nonlinear association between
PD and PM2.5 but no significant association was observed among those ≥70 years
old. In the sex-stratified analysis, in females we found a positive significant nonlinear
association reaching a plateau in higher concentrations and a marginally significant
linear association in males (RR=1.02, 95% CI: 1.00–1.03). However, the evidence for
differences across sexes was not strong based on the mostly overlapping CIs (Figure 2.5).
For ALS, the exposure–response association remained linear across subpopulations.
We found no evidence of effect modification by sex based on overlapping CIs, but we
found some evidence for effect modification by age. In the ≥70 years age group, we
observed a significant negative estimate (RR=0.95, 95% CI: 0.91–0.99) and a positive
estimate in the group <70 (RR=1.04, 95% CI: 1.00–1.08; Figure 2.2).
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Figure 2.4: Exposure to PM2.5 and AD first hospitalization by age and sex
groups: Exposure–response association in AD patients by age (left): <70 (gray) and
≥ 70 (green) years; and by sex (right): among females (magenta) and males (blue).
The x-axes show the PM2.5 concentration distribution from 5
th to 95th percentile and
the y-axes the RR relative to the overall mean PM2.5 concentration (8.0 μg/m
3). The
shaded areas indicate the 95% confidence bands.
39
Figure 2.5: Exposure to PM2.5 and PD first hospitalization by age and sex
groups: Exposure–response association in PD patients by age (left): <70 (gray) and
≥ 70 (green) years; and by sex (right): among females (magenta) and males (blue).
The x-axes show the PM2.5 concentration distribution from 5
th to 95th percentile and
the y-axes the RR relative to the total mean PM2.5 concentration (8.0 μg/m
3). The
shaded areas indicate the 95% confidence bands.
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Sensitivity Analysis
In the sensitivity analysis, which included only patients with at least two hospi-
talizations with a primary or secondary discharge code for each outcome, the first
hospitalization counts were: 35,587 AD, 67,579 PD and 2269 ALS cases. The overall
association between exposure and hospitalization rate remained nonlinear and signif-
icant for PD (RR=1.22, 95% CI: 1.16–1.34 for a PM2.5 increase from 8 to 10 μg/m
3)
(Figure 2.6), and null for ALS (RR=0.95, 95% CI: 0.67–1.34). In the case of AD, the
association remained nonlinear, but it became significant, with stronger associations at
lower PM2.5 levels (e.g., RR=1.15, 95% CI: 1.02–1.28 for a PM2.5 increase from 8 to 10
μg/m3) that plateaued at concentrations above approximately 9 μg/m3 (Figure 2.6).
Figure 2.6: AD and PD sensitivity analysis. Exposure to PM2.5 and hospitaliza-
tions for AD (top) and PD (bottom), restricted to cases with at least two hospitaliza-
tions of AD or PD. Associations are based on evaluation of exposure over a 15-years
period in a per county analysis in NYS. The x-axes show annual mean PM2.5 concen-
trations and the y-axes the RR relative to the mean PM2.5 concentration (8.0 μg/m
3).
In the appendix, we included a summary figure of the effect estimates (Figure 2.7).
For the nonlinear associations, the effect estimates were calculated in three different
regions of the curve. In addition, for comparison, we also included the effect estimates
from the liner models of the main analysis.
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2.5 Discussion
We conducted a NYS-wide study to estimate the impact of long-term PM2.5 county-
wide exposure on clinical aggravation of AD, PD, and ALS. We used a patient’s first
hospitalization with a primary or secondary diagnosis of AD, PD, or ALS as a proxy for
disease aggravation. By focusing on incidence of first hospitalization, we captured the
crossing point when clinical symptoms become more severe to require hospitalization.
With this design, we assume that patients who become more clinically ill are more
likely to be hospitalized. We characterized the overall exposure–response curves for
each outcome, as well as the association in subpopulations of <70, and ≥70 years of
age, and among males and females. We leveraged data from SPARCS and a well-
validated air pollution prediction model at high spatial resolution. Our study over
15 years included 384,158 subjects. The present study provides several novel insights,
including examination of long-term PM2.5 exposure in association with PD, AD, and
ALS first hospitalization in two different age subgroups.
We found that exposure to increasing concentrations of PM2.5 resulted in increasing
first hospitalization rates for PD but not for AD or ALS. In the sensitivity analy-
sis, however, we also observed a positive association between PM2.5 exposure and AD
hospitalizations. The sensitivity analysis had stricter inclusion criteria which likely
eliminated a number of false positives — under ICD-9, AD cases are frequently mis-
classified (Pippenger et al., 2001). Outcome misclassification could also result in a
number of false negatives. Based on our data, the average annual hospitalization rates
per 100,000 population were 91.2 for AD, 42 for PD and 1.9 for ALS. Comparing the
hospitalization rate in our data to reported disease incidence (Lopez and Kuller, 2019;
Hirsch et al., 2016; Lix et al., 2010; Niu et al., 2017; Talbott et al., 2014; Hirtz et al.,
2007), AD first hospitalizations, unlike PD and ALS, capture only a small percentage
of the potential total AD cases (91.2 vs 1000 cases per 100,000). The difference between
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AD first hospitalization rate and AD disease incidence can result from false negatives
due to outcome misclassification or from fewer AD patients requiring hospitalization
even in severe stages of the disease. Both of these factors could explain our null findings
for AD in the main analysis. Indeed, in our sensitivity analysis removing potentially
erroneous AD cases, we observed statistically significant harmful effects.
In the stratified analyses, we found insufficient evidence of effect modification by
sex for all outcomes. Previous studies have reported similar findings on sex effect
modification (Shin et al., 2018; Kioumourtzoglou et al., 2015). Although we did not
find significant differences by sex, in PD we observed a seemingly stronger association
between PM2.5 exposure and PD first hospitalization rates in females compared to
males. Previous studies reported stronger association of PM2.5 exposure with risk and
aggravation of PD among females relative to males, (Liu et al., 2016; Lee et al., 2017),
which aligns with our findings. A study in a cohort of female nurses, however, reported
a null association with disease risk (Palacios et al., 2014). Overall, effect modification
by sex in PM2.5–PD is inconclusive and requires further study.
Unlike sex effect modification, to our knowledge, no previous studies have exam-
ined effect modification by age in these outcomes. We observed a positive association
between PM2.5 exposure and increased PD and AD hospitalization rates in patients
<70 years old with an overall similar nonlinear curve shape that plateaued at higher
concentrations. This association was not apparent among those ≥70. Other long-term
PM2.5 exposure studies have seen similar curves that plateau at higher concentrations
in mortality outcomes (Burnett et al., 2018). For AD, the effect modification by age
was not significant but for PD it was at levels below 10 μg/m3. For ALS, we also found
a positive linear association between long-term exposure to PM2.5 and ALS patients
<70 but a negative association in patients ≥70 years. A previous ALS cohort study,
including patients age 57-70 years, found a positive association between PM2.5 expo-
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sure and risk of ALS (Seelen et al., 2017) which aligns with our findings. However, the
protective effect among those ≥70 is unexpected. It is important to note that our per
county ALS counts were particularly low in the stratified analysis, thus, more studies
are required to confirm any potential associations by age, positive or negative.
Based on our results, patients with a first hospitalization before 70 years may be
particularly vulnerable to PM2.5 exposure. In contrast, patients who have their first
hospitalization at a later age (≥70) may have an overall better health status and, thus,
be less affected by PM2.5 exposure. Since we are using primary and secondary diag-
noses, patients with a first hospitalization at a younger age may have stronger genetic
predispositions or coexisting medical conditions that render patients with higher sen-
sitivity to PM2.5 exposure. Importantly, we do not identify the <70 age period as
a vulnerable window of exposure during which PM2.5 exposure can aggravate clinical
symptoms of the disease; instead, patients within these age group may share under-
lying characteristics that increase their vulnerability to PM2.5 exposure. Nevertheless,
although the effect modification by age was not significant for AD, and only for part
of the exposure range for PD, our results indicate that PM2.5 exposure likely has dif-
ferential effects among different subpopulations of patients with potential associations
in this age group requiring further exploration.
Strengths and Limitations
This study has several strengths. Disease prognosis varies greatly in neurodegener-
ative diseases and the nature for such variation is still largely unknown. This is one of
the few epidemiological studies that address this knowledge gap. Here, we evaluated
long-term exposure to PM2.5 as a potential contributor to clinical aggravation of PD,
AD and ALS. Moreover, our study covers a geographical area that includes both ur-
ban and rural locations and a diverse population with a broad range of ages, allowing
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us to evaluate age subpopulations. Other studies using hospitalizations to examine
this association in the US have leveraged the Medicare population that only includes
enrollees >65 years, old (Kioumourtzoglou et al., 2015; Lee et al., 2019). SPARCS
includes information on hospitalizations of all ages. Furthermore, health data for the
years 1995–1999 allowed us to exclude any potential prevalent cases. Finally, we used
flexible models to characterize the exposure–response relationships.
However, our findings should be interpreted in light of our limitations. Since
SPARCS only includes information on hospitalizations, we did not have data on non-
cases to perform an individual-level time-to-event analysis. Furthermore, due to small
numbers — especially for ALS — we aggregated analyses at the county level. We
used predicted PM2.5 concentrations to assign county-level exposures. The prediction
model has excellent predictive accuracy(Van Donkelaar et al., 2019) and is highly spa-
tially resolved to capture county-level population-average exposures, but some exposure
measurement error is still expected. Any resulting bias, however, is expected to be to-
wards the null (Kioumourtzoglou et al., 2014; Hart et al., 2015; Wu et al., 2019). First
hospitalization data are likely to miss a number of cases, as patients may not be hos-
pitalized even as disease symptoms worsen. Patients with neurodegenerative diseases
are often admitted into nursing homes, particularly when the disease begins to worsen.
However, although first hospitalization is not specific to disease aggravation, it cap-
tures a significant number of cases entering a severe stage of the disease (Oguh and
Videnovic, 2012; Albert et al., 1999; Lechtzin et al., 2001). To our knowledge, data on
clinical aggravation of disease, with specific biomarkers or scores, are not available for
large cohorts living over large areas to allow for adequate exposure contrasts.
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2.6 Conclusion
Exposure to PM2.5 has been consistently associated with systemic inflammation,
which in turn is linked to neuroinflammation. (Block and Calderón-Garcidueñas, 2009;
Genc et al., 2012; Calderón-Garcidueñas et al., 2008; Feng et al., 2016; Block et al.,
2007) Whether this pathophysiological process contributes to disease aggravation in pa-
tients with neurodegenerative diseases is still unknown. In our study, we estimated the
effect of long-term PM2.5 exposure on AD, PD, and ALS clinical disease exacerbation
using first hospitalization as a surrogate. The effects of long-term exposure to low-to-
moderate PM2.5 concentrations, as the ones we found in NYS (8 μg/m
3 on average) and
most developed countries, are largely unknown. Our findings indicate that increases
in annual PM2.5 exposure potentially contribute to clinical disease aggravation in PD,
AD and in certain ALS age subpopulations. Identifying environmental contributors to
neurodegenerative diseases and sensitive population subgroups could lead to the de-
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Table 2.2: Counts by age and sex for each of the outcomes
<70 ≥ 70 Total Net Total
AD 263,861
Female 9,478 167,400 176,878
Male 7,890 79,093 86,983
PD 114,147
Female 10,799 42,708 53,507
Male 15,172 45,468 60,640
ALS 5,569
Female 1,460 1,061 2,521
Male 1,994 1,052 3,046
384,158
52
Figure 2.7: Effect estimates for the association between annual PM2.5 exposure and first hospitalization for AD
or PD at three different points across the nonlinear exposure–response curve. The x-axis shows the strata and
the y-axis the rate ratios (RR). Error bars indicate 95% CI. The square refers to the RR at PM2.5 concentration 8 relative to
6μg/m3; the black circle, the RR at PM2.5 concentration 10 relative to 8 μg/m
3; and the triangle, the RR at concentration
12 relative to 10 μg/m3. The linear relationships are shown in orange per 2 μg/m3 increase in PM2.5 for the strata in which
we detected no deviations from linearity. For comparison, we also included the linear effect estimates from the main analyses
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Background: Increasing evidence suggests that long-term exposure to fine partic-
ulate matter (PM2.5) may contribute to neurodegenerative diseases, including disease
aggravation in Parkinson’s disease (PD). In this study, we expanded upon previous
findings by characterizing the association of six PM2.5 components with PD aggrava-
tion.
Methods: We used first hospital admissions with a PD diagnosis as a proxy for
disease aggravation. We obtained data from the New York Department of Health
Statewide Planning and Research Cooperative System (2000–2014) to calculate an-
nual PD first hospitalizations in New York State (NYS) and a well-validated predic-
tion model to estimate population-weighted annual black carbon (BC), organic matter
(OM), nitrate, sulfate, sea salt (SS), and soil particle concentrations at the county level.
We used a multi-pollutant mixed quasi-Poisson model with county-specific random
intercepts to examine the association of PM2.5 components with PD disease aggrava-
tion. We evaluated potential nonlinear exposure–outcome relationships using penalized
splines and accounted for potential confounders.
Results: We observed a total of 114,514 hospitalisations for PD in NYS from 2000–
2014. The hospitalization annual average count per county was 131. We observed
significant linear nitrate–PD (RR = 1.05, 95%CI: 1.02–1.09 per one standard deviation
(SD) increase) and OM–PD (RR = 1.05, 95%CI: 1.02–1.07 per SD increase) associations
and a nonlinear association for BC with a negative slope at high concentrations. We
found no evidence of association with sulfate, SS and soil.
Conclusion: Our findings suggest that annual increases in county-level OM and ni-
trate particles are potentially associated with disease aggravation in PD.
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3.2 Introduction
Particulate matter with a diameter ≤ 2.5 μm (PM2.5) is a dynamic heterogeneous
mixture that continuously changes over time and space. The main components of PM2.5
include ammonium sulfate, crustal material, black carbon (BC), ammonium nitrate, sea
salt (SS), trace element oxides, and residual matter (Snider et al., 2016; Van Donkelaar
et al., 2019). Research has shown that exposure to PM2.5 can contribute to ischemic
heart disease, cerebrovascular disease, lung cancer, chronic obstructive pulmonary dis-
ease, lower-respiratory infections, and diabetes, among others (Andersen et al., 2012;
Anderson et al., 2012; Naghavi et al., 2017; Yang et al., 2018; Liu et al., 2016). More
recently, studies have also identified long-term PM2.5 exposure as a potential risk factor
for neurodegenerative diseases (Liu et al., 2016; Palacios et al., 2014; Fu et al., 2019;
Shin et al., 2018; Kioumourtzoglou et al., 2015b; Ritz et al., 2016; Calderón-Garcidueñas
et al., 2016).
PD is the second most prevalent neurodegenerative disease worldwide, affecting 1-2
per 1000 of the population at any given time (Hirsch et al., 2016; Lix et al., 2010).
PD neuropathology is characterized by α-synuclein-containing Lewy bodies and loss
of dopaminergic neurons in the substantia nigra, manifesting mainly as tremor, rigid-
ity, and bradykinesia; however, its exact pathogenesis remains unclear (Tysnes and
Storstein, 2017). In addition to acknowledged and unknown genetic factors, environ-
mental exposures are also suggested to influence disease expression (Chin-Chan et al.,
2015; Elbaz et al., 2016; Tysnes and Storstein, 2017; Poewe and Wenning, 1998; Poewe,
2006).
A couple of epidemiological studies have investigated the association of PM2.5 ex-
posure with increased PD risk (Kirrane et al., 2015; Liu et al., 2016; Palacios et al.,
2014) and disease aggravation (Kioumourtzoglou et al., 2015b). The studies that as-
sessed PM2.5 exposure and risk for PD in the Agricultural Health Study cohort and
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the Nurses’ Health Study found marginally positive and null associations, respectively
(Kirrane et al., 2015; Palacios et al., 2014). In the PAGE case-control study, the
association was positive only among women (Liu et al., 2015) and in US Medicare ben-
eficiaries living in urban centers, PM2.5 exposure was positively associated with disease
progression (Kioumourtzoglou et al., 2015b). Among other factors (e.g., windows of
exposure, adjustment for confounders, exposure measurement error and study design),
discrepancies on findings could partially result from varying risk by PM2.5 composition.
The above studies were conducted in different populations residing in different places.
However, composition of PM2.5 varies in space and time (Bell et al., 2007; Austin et al.,
2013) and can modify PM2.5 estimated health effects (e.g., survival, (Kioumourtzoglou
et al., 2015a)), which could also contribute to the observed differences across PM2.5–PD
studies.
In Chapter 2, we reported a positive association between long-term exposure to
total PM2.5 mass and disease aggravation in PD. Here, to further our understanding of
this relationship, we characterized long-term exposure to six specific PM2.5 components:
BC, organic matter (OM), sulfate, nitrate, SS, and soil. We examined each component’s
independent association with PD first hospitalization rates to identify those components
that contribute to disease aggravation in PD. We used data on first PD hospitalizations
from all of NYS from 2000–2014 and air pollution estimates from a previously validated
model (Van Donkelaar et al., 2019). Identifying specific PM2.5 components that lead
to adverse health effects can help elucidate potential biological mechanisms by which
PM2.5 contributes to neurodegeneration in PD and also provide valuable information




We obtained patient data from the New York Department of Health Statewide
Planning and Research Cooperative System (SPARCS), a comprehensive data reporting
system that collects information on hospital admissions and emergency department
(ED) visits within NYS. SPARCS data include information on approximately 98% of all
hospitalizations in non-federal acute care facilities, regardless of insurance status. The
dataset also contains patients’ demographics, including age, sex, and patient residential
address. At the first hospitalization, a unique ID is assigned to the patient, which allows
for patient tracking over time. We used SPARCS data on first hospitalizations and ED
visits for PD from 2000 to 2014. To remove potentially prevalent cases, using SPARCS
data from 1995–1999, we identified patients with first admissions that occurred prior to
2000 and removed them from the dataset. We obtained approval to conduct the analysis
from Columbia University Institutional Review Board. The same board waived the need
for informed consent because of the public nature of the data.
Outcome Definition
We extracted all hospitalizations and ED visits with International Classification of
Diseases ninth revision (ICD-9) code 332.0, which specifically corresponds to PD. We
used both primary and secondary discharge codes. Hospitalizations with a primary
diagnosis of PD include hospitalizations for conditions directly related to PD, such as
motor complications or cognitive and psychiatric impairments. Hospitalizations with
a secondary diagnosis of PD had a health condition unrelated or indirectly related
to PD (e.g., falls, infections) as the primary reason of hospitalization (Figure 2.1).
We restricted our study to first hospitalizations. By focusing on incidence of first
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hospitalization, we evaluated whether exposure is associated with cases developing —
for the first time — clinical symptoms severe enough to require hospitalization. Our
outcome definition, thus, captures the crossing point to a more severe clinical stage of
PD, a proxy for disease exacerbation.
Air pollution Data
Annual PM2.5 BC, nitrate, sulfate, OM, SS, and soil mass concentrations were pre-
dicted by a well-validated air pollution prediction model (Van Donkelaar et al., 2019).
Briefly, the PM2.5 total mass was derived from satellite retrievals, then partitioned into
chemical composition using a chemical transport model. The resulting mass estimates
were then statistically fused with ground-based measurements to yield an accurate
continuous surface despite sparse composition of monitor density. This model performs
well, with cross-validated R2 values ranging from 0.67 to 0.96 with the strongest agree-
ment for sulfate (R2 = 0.96) and nitrate (R2 = 0.90) and the lowest for OM (R2 =
0.67). We estimated annual population-weighted county averages for each component
and total PM2.5 by first averaging the predicted annual concentrations over all grids
within a county subdivision (minor civil county division, e.g. towns and townships),
then calculated a county average in which we weighted more those county subdivisions
with larger populations. Lastly, we scaled concentrations by dividing by the respective
component’s standard deviation (SD) to present effect estimates of linear associations
per one SD increase and facilitate comparability of estimates across components. We




The unit of analysis in our study design is county-year because we used annual ag-
gregated counts of PD hospitalizations per county. As a result, potential confounders
can only be variables that vary from year to year and across counties, and co-vary both
with the outcome (PD hospital admission counts) and the exposure (PM2.5 compo-
nents). Thus, in this study design, individual-level variables cannot act as confounders.
To account for potential spatial confounding, we included county-specific socioeco-
nomic status (SES) variables obtained from the US Census Bureau and the American
Community Survey for the years 2000, 2004–2014. Data included median household
income, percent of residents below poverty, percent of residents without a high school
degree, and racial/ethnic distribution (proportion of White, Asian, Black and Hispanic
residents). We also included county-level smoking prevalence and percent obesity data
obtained from the Behavioral Risk Factor Surveillance System. For the above con-
founder variables, we interpolated years without available data (2001–2003) using a
generalized additive model with a penalized spline for year to allow for nonlinear time
trends.
To account for potential temporal confounding, we adjusted for long-term trends
using calendar year and summer and winter mean temperatures. We retrieved daily
mean temperatures at a 1/8th-degree grid from the North America Land Data Assim-
ilation System (Mitchell et al., 2004). We calculated monthly mean temperatures at
the county level from daily temperatures over all grids within a county, then averaged
June–August and December–February estimates to obtain the summer and winter mean
temperature, respectively, for each year.
In the sensitivity analysis, we also included total PM2.5 mass concentration as a
potential confounder. By adjusting for total PM2.5 mass, we are adjusting for other
sources/components of PM2.5 that may be correlated both with each component and
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the outcome, thus potentially inducing confounding (Mostofsky et al., 2012).
Statistical Analysis
We ran a multi-pollutant model that included all PM2.5 components simultaneously
— BC, nitrate, OM, sulfate, soil, and SS. This allowed us to evaluate independent
component associations with PD first hospitalization rates, adjusting for other PM2.5
components. With the multi-pollutant model, we assessed how annual county-wide
increases in a given component affect annual rates of first PD hospitalization when
keeping all other components’ concentrations constant.
For our analysis, we used a variant of the difference-in-differences causal approach
(Wang et al., 2016). We estimated associations using a generalized additive mixed
model to allow for nonlinear exposure–outcome relationships and the inclusion of both
fixed and random effects. We used county-specific random intercepts to account for
within-county clustering and allowed shared information across counties and included
county population size as the offset term in the model. We used a quasi-Poisson re-
gression, which allows for potential overdispersion in the outcome.
We followed a rigorous process to avoid potential misspecification in the model.
We first included all terms (exposure and potential confounders) linearly in the model.
Then, we used penalized splines for all continuous covariates to allow for any potential
nonlinear confounding. Once we identified the nonlinear confounders, we included a
penalized spline for each of the PM2.5 components to comprehensively characterize the
exposure–response relationships and identify potential deviations from linearity. We
reported the linear associations for all PM2.5 components along with the nonlinear
associations for those components for which we detected nonlinearity. For all penalized
splines, we used generalized cross-validation and the Akaike information criterion to




Correlation among PM2.5 components may result in collinearity when including
them simultaneously in a multiple regression. Thus, to assess the robustness of our
multi-pollutant model and the stability of our findings, we conducted a sensitivity anal-
ysis to further evaluate the exposure–response relationship of each component with the
outcome. For this, we ran separate models for each PM2.5 component. The component-
specific models included only one PM2.5 component, but, in addition to the other
confounders, were adjusted for total PM2.5 mass concentration using the population-
weighted county-year PM2.5 average. To build the component-specific models (total of
six models), we followed the same steps as in the main analysis.
For all analyses, the linear results are presented as rate ratios (RR) per one SD
increase in the annual concentration of a given PM2.5 component along with 95% con-
fidence intervals (CI). For components for which we detected deviations from linearity,
we also presented the entire exposure–response curve and the corresponding confidence
bands. All analyses were performed using the R Statistical Software version 3.6.1
(Foundation for Statistical Computing, Vienna, Austria).
3.4 Results
Study Population Characteristics
We included data from all 62 NYS counties. The average number of PD hospi-
talizations per year per county was 131 with a standard deviation (SD) of 222. We
observed 114,514 PD first hospitalizations (either as primary or secondary diagnoses)
over the 15-year period. The most common primary diagnosis category was Diseases
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of the Circulatory System which includes cardiovascular diseases (15.35%); the second
most common category was Diseases of the Nervous System (13.4%), of which 64% were
PD diagnoses; and the third most common primary diagnosis category was Injuries &
Poisoning which includes bone fractures (10.88%). Hospitalizations with a primary di-
agnosis of PD specifically, accounted for 9.47% of the total hospitalizations (Figure 2.1.
Of the total cases, 46.8% were females and 77.2% were ≥ 70 years old. Across counties,
the mean age (SD) at first hospitalization was 76 (1.0) years. Descriptive statistics for
the outcome and covariates are presented in Table 3.1.
PM2.5 component Characteristics
The summary statistics and distributions for each PM2.5 component are presented
in Table 3.1 and Figure 3.1, respectively. On average, we observed the highest concen-
trations for OM and lowest for SS. OM and sulfate made up most of the PM2.5 total
mass (35% and 31% on average, respectively). We observed variation in the concentra-
tions of components across counties and years and an overall decrease in concentrations
for all components over time. Figure 3.7 illustrates the concentrations of the PM2.5
components by county across NYS for the years 2000, 2007 and 2014. The Spear-
man correlation coefficients among components ranged from 0.36 to 0.78. We observed
the highest correlation between soil and nitrate (0.78), followed by sulfate and nitrate
(0.69), then sulfate and soil (0.68). Nitrate and sulfate had the strongest correlations
with PM2.5 0.81 and 0.88 respectively (Figure 3.2).
Exposure–Response Relationships
In the main analysis, we found than a one SD concentration increase in OM (RR
= 1.05, 95% CI: 1.02–1.07) or nitrate (RR = 1.05, 95% CI: 1.02–1.09) leads to a 5%
increase in PD first hospitalization rate. In the case of BC, we found a negative effect
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Table 3.1: Descriptive statistics based on annual per county estimates from 2000–2014
in NYS.
Mean St Dev 25% Median 75%
Outcome
PD 131.1 222.0 21.0 37.0 121.0
Female 57.8 98.8 9.0 16.0 52.0
Male 65.4 110.0 11.0 19.0 60.0
Component (μg/m3)
PM2.5 8.10 2.30 6.40 7.60 9.20
Black Carbon 0.66 0.24 0.51 0.59 0.71
Nitrate 0.96 0.33 0.73 0.91 1.14
Organic Matter 2.87 0.67 2.36 2.74 3.30
Sulfate 2.51 0.87 1.79 2.41 3.09
Soil 0.29 0.10 0.22 0.28 0.33
Sea Salt 0.26 0.16 0.15 0.21 0.32
Covariates
Median income (×$1000) 49.1 12.6 41.3 45.7 52.4
Percent below poverty 12.9 4.1 10.4 12.6 14.9
Percent w/o high school 18.1 7.3 12.8 17.3 22.2
Percent smoking prevalence 22.9 3.9 20.7 23.6 26.1
Percent obesity 25.0 4.5 22.3 25.4 27.8
Percent Hispanic 6.5 8.6 1.9 2.9 6.2
Percent White no Hispanic 83.6 16.8 80.3 90.2 94.0
Percent Black no Hispanic 5.7 6.3 1.4 3.4 7.5
Percent Asian no Hispanic 2.2 3.4 0.5 0.9 2.2
Summer mean temp. (oC) 20.2 1.5 19.2 20.2 21.1
Winter mean temp. (oC) -3.1 2.5 -4.9 -3.3 -1.5
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Figure 3.1: Density histrograms of PM2.5 components. Component distributions
are based on annual population-weighted county average concentrations from 2000–2014
across all counties in NYS. The x-axis indicates the average concentration (μg/m3) and
the y-axis the density.
estimate (RR = 0.96, 95%CI: 0.94–0.98) and observed null associations for SS, soil,
and sulfate (Figure 3.3). When we allowed for nonlinearity, BC and sulfate associa-
tions with the outcome deviated from linearity. For sulfate, the nonlinear association
remained null, and for BC the association was null in low concentrations but reached
significance at high exposure levels (above 1.3 μg/m3, i.e., the 96th percentile of the
BC concentration distribution) with higher concentrations associated with a lower RR
(Figure 3.4).
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Figure 3.2: PM2.5 component correlations. Spearman correlation coefficients were
estimated from the scaled annual population-weighted county average concentrations
from 2000–2014 in all counties across NYS.
Sensitivity Analysis
As sensitivity analysis, we ran component-specific models adjusted for PM2.5 mass
concentration. We saw an even stronger positive association between PD first hospital-
ization and nitrate concentrations (RR = 1.06, 95% CI: 1.02–1.09) and continue to see
a negative association between the outcome and BC (RR = 0.94, 95% CI: 0.91–0.96).
In the case of OM, the association remained positive but only marginally significant
(RR = 1.03, 95% CI: 0.99–1.06). For SS, soil, and sulfate we continued to see a null
association (Figure 3.6). When allowing nonlinearities, BC and sulfate deviated from
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Figure 3.3: RR derived from the multi-pollutant linear model. The effect
estimates correspond to the rate ratios of PD hospitalization per one SD increase in
annual exposure of a given component. The estimates are based on hospitalization and
exposure data from years 2000–2014. The estimates represent RR and bars 95% CI.
linearity. The exposure–response curve for BC was similar to the one observed in the
main analysis — only higher BC concentrations negatively associated with the outcome.
In the case of sulfate, the overall nonlinear association remained null (Figure 3.6).
3.5 Discussion
In Chapter 2, we observed a strong positive association between long-term exposure
to PM2.5 and PD first hospitalization rates in NYS. Here, we conducted a follow-
up study to identify specific PM2.5 components that may contribute to the observed
PM2.5–PD aggravation association. We characterized the exposure–response curves for
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Figure 3.4: Nonlinear association between first PD hospitalization and annual
exposure to BC (top) or sulfate (bottom). The solid black lines indicate the
exposure–response curves as RR relative to the mean BC (0.67 μg/m3) or sulfate (2.50
μg/m3) concentration. The gray shaded areas correspond to 95% confidence bands.
The relationships were obtained from the multi-pollutant model, adjusting for potential
confounders.
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Figure 3.5: RR obtained from the component-specific models (sensitivity
analysis). The effect estimates correspond to the increase in PD hospitalization rate
per one SD increase in annual exposure to a given component. The estimates are based
on hospitalization and exposure data from years 2000–2014. The estimates represent
RR and bars 95% CI. Component-specific models were adjusted for total PM2.5 mass
concentration and other potential confounders.
six PM2.5 components that constitute a large proportion of the total PM2.5 mass in
NYS. We leveraged data from well-validated prediction models at high spatial resolu-
tion and comprehensive hospitalization data from SPARCS. We used a patient’s first
hospitalization with a primary or secondary diagnosis of PD as a proxy for disease ag-
gravation. By focusing on incidence of first PD hospitalization, we aimed to capture the
crossing point when clinical symptoms become more severe to require hospitalization
(disease aggravation). With this design, we assume that patients who become more
clinically ill are more likely to be hospitalized. The present study provides novel insight
in identifying PM2.5 components that pose a risk for aggravation of clinical symptoms
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Figure 3.6: Exposure–response curves for first PD hospitalizations and annual
exposure to BC (left) or sulfate (right) from component-specific models
(sensitivity analysis). Models were adjusted for total PM2.5 mass concentration and
other potential confounders. The solid black lines indicate the exposure–response curve
between the component and PD first hospital admission as RR relative to the mean BC
(0.67 μg/m3) or sulfate (2.50 μg/m3) concentration. The gray shaded areas correspond
to 95% confidence bands.
in PD.
In summary, we found that increases in annual OM and nitrate concentrations were
independently associated with increased first PD hospitalization rates. For BC, we
observed a nonlinear association that was null at low concentrations, but significantly
negative above the 96th concentration percentile, while for SS, soil, and sulfate the
associations were null. Our findings were robust to sensitivity analyses.
The BC component of PM2.5 consists of soot, charcoal, char and other light absorb-
ing refractory matter. BC is a product of incomplete combustion, mainly associated
with traffic-related pollution in urban settings and concentrated next to busy roads and
highways (Tomasi et al., 2017). Although the health effects of BC on cognition have
been well-studied (Suglia et al., 2008; Colicino et al., 2016; Clifford et al., 2016), its
contribution to neurodegenerative disorders, such as PD, is not as well characterized.
A study by Toro et al. (2019) is the only other epidemiological study that has evaluated
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the long-term effects of BC exposure on PD. The study was a case-control analysis in
the Netherlands based on residence-level exposure; in this study, the authors reported
a null association. Chen et al. (2017) examined the association between residential
proximity to road and clinical diagnosis of PD in an Ontario population cohort and
also found a null association. However, two other studies in Denmark and Taiwan have
linked other traffic-related pollutants (nitrate oxide and carbon monoxide) with risk of
PD (Ritz et al., 2016; Lee et al., 2016). In NYS, for a one-year exposure window, we
observed a null association between BC and PD first hospitalization rate for essentially
the entire BC distribution, but found an unexpected negative association at very high
concentrations, i.e., above the 96th percentile of the BC distribution (∼1.3 μg/m3). It
is possible that presence of outlying values at high BC concentrations may have influ-
enced the observed association. Further studies examining the effects of BC at such
high levels of exposure are important to confirm our findings for BC.
Although we did not observe an association with BC, we did see a consistent associa-
tion with nitrate. Nitrate is mainly a secondary particle found in the atmosphere in the
form of ammonium nitrate (Tomasi et al., 2017). The nitrate originates primarily from
nitrogen oxides which are mainly emitted to the atmosphere by fossil fuel combustion,
with vehicles and electric utility sectors being the major contributors (Howarth et al.,
2002; Lloret and Valiela, 2016). In NYS, formation of ammonium nitrate particles is
limited by ammonia availability. Ammonia primarily originates from agricultural activ-
ities and livestock farming; however, recent studies suggest that in urban areas, traffic
is a primary contributor of atmospheric ammonia (Sun et al., 2014; Shon et al., 2012).
Temporal studies of ammonia concentration in NYS indicate that traffic and population
centers are important sources of ammonia in the state (Zhou et al., 2019). Therefore,
nitrate particles can be considered as a good surrogate for traffic in NYS. The adverse
health effects resulting from nitrate exposure have been less explored. Three studies
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have linked nitrate exposure with all-cause mortality (Ostro et al., 2007; Cao et al.,
2012; Hoek et al., 2000) and one study with cardiovascular- and respiratory-related
mortality (Cao et al., 2012). In our study, we observed a consistent increase in annual
PD hospitalization rates related to increased annual nitrate concentrations. Although
there is no previous evidence indicating an association between nitrate exposure and
disease aggravation in PD, Ritz et al. (2016) and Lee et al. (2016) linked nitrate oxide
and carbon monoxide, both traffic-related pollutants, with risk for PD. However, be-
cause we observed no evidence of a positive association between the outcome and BC,
it is possible that nitrate represents a different part of traffic.
Sulfate is also mainly a secondary particle found in the atmosphere in the form
of ammonium sulfate. We get sulfate for the most part from regional transport in the
summer (e.g., from the coal power plant emissions upwind from NYS). Similarly to BC,
sulfate is one of the most studied PM2.5 components in epidemiological studies. Various
studies have linked sulfate exposure with adverse respiratory and cardiovascular effects,
as well as mortality (Pope III et al., 2007; Lepeule et al., 2012; Schwartz et al., 1996;
Chen et al., 2018; Jones et al., 2015; Brook et al., 2007; Ito et al., 2011; Gwynn et al.,
2000; Atkinson et al., 2015), but no studies to date have examined the association with
neurodegeneration. In our study, we found a null association between sulfate exposure
and disease aggravation in PD. However, since the literature in this area is limited,
we encourage other studies to analyze this potential relationship, preferentially with
individual-level exposure assessment, to confirm our findings.
The OM component of PM2.5 is a mixture of primary and secondary organic par-
ticles that includes hundreds of compounds such as organic carbon, polycyclic aro-
matic hydrocarbons (PAH), alkanes, and fatty acids (Jacobson et al., 2000). Some OM
compounds have known toxicity, for example PAHs are known carcinogens and im-
munosuppressants (Abdel-Shafy and Mansour, 2016), but the wide variety of organic
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compounds present in PM2.5 remains largely uncharacterized (Jacobson et al., 2000).
OM constitutes a large percentage of PM2.5 in some regions, including NYS; however,
the contribution of OM to the adverse effects of PM2.5 on the nervous system is still
largely unknown. Some studies have linked prenatal and postnatal exposure to PAHs
with neurodevelopmental disturbances, impaired learning and memory deficits in chil-
dren (Peterson et al., 2015), inflammatory responses in vitro and in vivo (Den Hartigh
et al., 2010), and degenerative disease-like syndromes in zebrafish (Gao et al., 2015).
Here, we observed a consistent positive association between OM exposure and disease
aggravation in PD. The composition of OM in PM2.5 is highly complex and may differ
from region to region, as well. Given its high neurotoxic potential, it is imperative to in-
crease the number of studies evaluating its association with neurodegenerative diseases,
such as PD.
Overall, our results indicate that PM2.5 compositional profile likely plays a role in
its neurotoxicity. We observed positive associations for some — but not all — PM2.5
components, which may explain some of the variability observed across studies from
different regions. Estimating PM2.5 component-specific effects is important to elucidate
potential mechanisms by which PM2.5 exerts its adverse effects on neurodegeneration
and also for the development of targeted and source-specific regulations for particulate
matter. In our study, we observed that not all PM2.5 components are associated with
clinical aggravation of PD and identified nitrate and OM as particularly harmful PM2.5
components with stronger effect estimates observed for nitrate. To our knowledge,
this is the first study to analyze the effects of long-term exposure to specific PM2.5
components on clinical aggravation of PD.
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Figure 3.7: Population-weighted county averages for PM2.5 components across three
distinct years: 2000, 2007, and 2014.
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Strengths and Limitations
Our study has several strengths. The rate of disease aggravation upon clinical diag-
nosis varies greatly among PD patients, but the drivers of such variation are still largely
unknown. This is one of the few epidemiological studies to address this knowledge gap.
PM2.5 exposure has been identified as a potential risk factor for PD, but little is known
about the role specific PM2.5 components have on this association. Here, we evaluated
long-term exposure to six PM2.5 components and their association with clinical disease
aggravation in PD. Our study covers a geographical area that includes both urban and
rural locations and a diverse population. Other studies using hospitalizations to exam-
ine the PM2.5–PD association in the US have leveraged information from the Medicare
population which only includes enrollees ≥65 years old (Kioumourtzoglou et al., 2015b;
Lee et al., 2019). SPARCS includes information on hospitalizations of all ages and
independently of health insurance. Furthermore, available health data for the years
1995–1999 allowed us to exclude any potential prevalent cases. Finally, we used linear
and nonlinear models to characterize the exposure–response relationships.
However, our findings should be interpreted in light of our limitations. Since
SPARCS only includes information on hospitalizations, we did not have data on non-
cases to perform an individual-level time-to-event analysis. We used predicted PM2.5
component concentrations to assign county-level exposures. The prediction models have
good predictive accuracy(Van Donkelaar et al., 2019) and are highly spatially resolved
to capture county-level population-wide exposures, but some exposure measurement er-
ror is still expected. Specifically, the cross-validated R2 varied by PM2.5 component; we
would thus expect more error for OM. Furthermore, for components with high spatial
heterogeneity, such as BC, a county-wide average may inadequately reflect population
exposures. Any resulting bias, however, is likely towards the null (Kioumourtzoglou
et al., 2014; Hart et al., 2015; Wu et al., 2019). Although the PM2.5 components in this
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study account for a large portion of PM2.5 mass, they do not capture all PM2.5 compo-
nents. For instance, metals that account for a small percent of total PM2.5 mass were
not evaluated in this study, but they have been previously linked to PD (Finkelstein
and Jerrett, 2007; Willis et al., 2010). We also did not evaluate potential interactions or
additive effects among the components, which could also play a role in the overall PM2.5
neurotoxicity. First hospitalization data are likely to miss a number of the total cases,
as patients may not be hospitalized even as disease symptoms worsen. Patients with
neurodegenerative diseases are often admitted into nursing homes, particularly when
the disease begins to worsen. However, although first hospitalization is not specific to
disease aggravation, it captures a significant number of cases entering a severe stage of
the disease (Oguh and Videnovic, 2012; Albert et al., 1999; Lechtzin et al., 2001). To
our knowledge, data on clinical disease aggravation for PD, with specific biomarkers or
scores, are not available for large cohorts living over large areas to allow for adequate
exposure contrasts.
3.6 Conclusion
Exposure to PM2.5 has been consistently associated with systemic inflammation,
which in turn has been linked to neuroinflammation and other brain pathological pro-
cesses (Block and Calderón-Garcidueñas, 2009; Genc et al., 2012; Calderón-Garcidueñas
et al., 2008; Feng et al., 2016; Block et al., 2007). Whether these pathophysiological
responses contribute to disease aggravation in patients with neurodegenerative diseases
is still unknown. In Chapter 2, we reported a strong positive association between
long-term PM2.5 exposure and PD disease exacerbation using first hospitalization as
a surrogate. Here, we further characterized this association by estimating the effect
of specific PM2.5 components on PD first hospitalization rate. Our findings indicate
that long-term exposure to nitrate and OM PM2.5 potentially contributes to clinical
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disease aggravation in PD. The contribution of PM2.5 components to its overall adverse
health effects are largely unknown, particularly in the context of neurodegeneration.
Identifying specific PM2.5 components that contribute to neurodegenerative diseases
will bring insight into the potential mechanism of PM2.5 neurotoxicity and can inform
on the development of targeted preventive strategies to minimize harmful exposures.
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This dissertation aimed to help understand the relationships between PM2.5 ex-
posure and disease aggravation in neurodegenerative diseases and to identity specific
PM2.5 components that are associated with this outcome. In this chapter, we discuss
our findings and their implications in 3 main sections: in Section 4.1 we summarize our
results and discuss plausible biological pathways, in Section 4.2 we discuss future re-
search directions and lastly in Section 4.3 we talk about the public health implications
of our work.
4.1 Findings and plausible biological pathways
Summary of findings
We evaluated the association between county-level increases in annual PM2.5 con-
centration, and its components, and disease aggravation in three neurodegenerative
diseases: AD, PD, and ALS. In Chapter 2, we found a nonlinear association between
total PM2.5 exposure and PD hospitalizations which plateaued at higher concentrations
of PM2.5 (> 13 μg/m
3) (Figure 2.3). We also found that patients with a first PD hospi-
talization at age 70 or younger are at slightly higher risk for disease aggravation under
increasing PM2.5 exposures (Figure 2.5). In the case of AD, we observed evidence of a
potential association between annual increases in PM2.5 exposure and disease aggrava-
tion, but only in a sensitivity analysis aiming to decrease outcome misclassification. In
Chapter 3, we found a linear association between disease aggravation in PD and long-
term exposure to the PM2.5 components nitrate and OM. We observed a 5% increase
in first PD hospitalization rates with each one standard deviation increase in nitrate
(0.33 μg/m3) or OM (0.67 μg/m3) concentration (Figure 3.3).
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Potential biological mechanisms
The exact mechanism(s) by which PM2.5 mediates neurotoxicity or influences neu-
rodegeneration is still unclear. However, three points of PM2.5 entry have been identified
as relevant to the nervous system: 1) nasal cavity, 2) lower respiratory system and 3)
gastrointestinal (GI) track (Figure 4.1.
Nasal cavity. Sensory neurons in the nasal cavity connect with neurons in the ol-
factory bulb, which subsequently project to a third site of signal organization. This
site includes the orbitofrontal and insular cortices, thalamus, hypothalamus, and amyg-
dala (Ajmani et al., 2016). Various studies have reported the ability of some inhaled
compounds (e.g., Mn, Pb) to travel via neuronal axons from the nasal cavity to brain
regions (Hopkins et al., 2018; Horning et al., 2015). It is unlikely that PM2.5 particles
in the micrometer diameter size access the central nervous system (CNS) via neuronal
transport, but this is a plausible route for the smaller particles within the PM2.5 size
distribution, those in the nanometer scale (ultrafine particles). Furthermore, upon en-
trance to the nasal cavity, water-soluble components of particles, such as ammonium
nitrate, ammonium sulfate and some organic compounds (Speight, 2016), may dissolve
into the aqueous environment of the nasal mucosa and release ions or elements that
can either reach the CNS via nerve transport or initiate inflammatory responses in
the nasal cavity (Shusterman, 2011; Calderon-Garciduenas et al., 2002). Inflammation
triggered by particles in the nasal cavity can lead to olfactory dysfunction and other
local pathologies (Shusterman, 2011; Ajmani et al., 2016). Interestingly, pathology in
the olfactory system is observed in the early clinical stages of some neurodegenerative
diseases. For instance, disease processes in PD start in the dorsal motor nucleus of the
vagus and anterior olfactory nucleus and bulb and then progress to other parts of the
CNS (Lerner and Bagic, 2008). In fact, hyposmia, a decrease in the olfactory sense, is
observed in 90% of PD patients and often appears before clinically overt PD (Lerner and
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Bagic, 2008; Poewe, 2006). The adverse effects of inflammatory responses triggered by
PM2.5 in the nasal cavity (Cheng et al., 2016; Calderón-Garcidueñas et al., 2012; Chen
et al., 2012; Nikasinovic et al., 2006) have also been proposed to extend beyond the
olfactory system to affect other systems, including the CNS, via systemic inflammation
Pope III et al. (2016); Block and Calderón-Garcidueñas (2009); Calderon-Garciduenas
et al. (2002).
Lower respiratory system. PM2.5 is distinguished from coarse particles by its abil-
ity to reach the lower respiratory system due to the smaller particle size. Moreover,
ultrafine particles have been reported to translocate from the alveoli to the circulatory
system or interestitial space and reach other organs, but this has not been reported for
all particles in the PM2.5 size range (Maher et al., 2016; Calderón-Garcidueñas et al.,
2008; Stone et al., 2017; Miller et al., 2017). It has been widely reported that PM2.5
can initiate inflammatory responses that lead to inflammatory injury and increase the
lungs’ susceptibility to infections. PM2.5 can stimulate over-expression of a number of
inflammation-related cytokine genes, lead to an increase in the number of neuotrophils,
eosinophils, T cells, and mastocytes in the bronchoalveolar lavage fluid, and influence
the phenotype and function of alveolar macrophages (Xing et al., 2016). Although neu-
rodegenerative diseases are mainly characterized by neuronal degeneration, symptoms
go far beyond the CNS. For instance, one of the primary causes of death among PD
patients is pneumonia. PD patients are more likely to develop pneumonia than older
adults without PD (Poewe and Wenning, 1998; Poewe, 2006; Williams-Gray et al.,
2013; Pennington et al., 2010). This indicates that aggravation of neurodegenerative
diseases may include other health aspects and not necessarily just worsening of neu-
rological symptoms. Thus, the effects of PM2.5 in the lungs could also contribute to
deterioration of health in PD patients. Additionally, multiple studies indicate that in-
flammatory responses initiated in the lungs go far beyond the respiratory system and
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have the potential to trigger a systemic inflammation that can in turn damage other
systems, including the CNS (Pope III et al., 2016; Block and Calderón-Garcidueñas,
2009).
Gastrointestinal track. In addition to infiltrating the upper and lower respiratory
system, PM2.5 can also enter the digestive system directly or indirectly via mucocil-
iary clearance or swallowing of saliva and mucus (Beamish et al., 2011; Oberdörster,
1993; Semmler-Behnke et al., 2007). Research suggests that within the GI tract, PM2.5
may affect the GI epithelium. A study found that PM2.5 can trigger the production
of mitochondrial reactive oxygen species and inflammatory cytokines in epithelial cells
leading to increased gut permeability (Mutlu et al., 2011). Inflammatory responses in
the gut may affect the nervous system either indirectly via increased epithelial per-
meability and systemic inflammation or directly via the brain-gut axis (BGA) (Zhu
et al., 2020). The BGA connects the gut with the brain. It encompasses a highly
complex interactive network of endocrinological, immunological, and neural mediators
that modulate physiological stress responses and alimentary functions in the digestive
system (Ambrosini et al., 2019). Interestingly, patients with neurodegenerative dis-
eases often present concurrent intestinal lesions — histopathological changes in the GI
tract are observed even decades before neurodegenerative processes (Ambrosini et al.,
2019). PM2.5 exposure has also been suggested to alter the gut microbiota. Intesti-
nal microorganisms are a natural part of the gut flora and have a mutually beneficial
relationship with the human host. They closely interact with the host to directly or
indirectly influence various physiological functions (Shreiner et al., 2015). For instance,
the intestinal microbiota plays important roles in metabolic processes, protects against
pathogens, and educates the immune system — the immune system of an individual
must learn to tolerate the ”good” microbiota but respond appropriately to pathogens
(Shreiner et al., 2015). The microbiota of a healthy individual remains for the most
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part stable throughout a lifetime (Shreiner et al., 2015). However, animal studies sug-
gest that ingested PM2.5 can alter gut microbiota (Chen et al., 2019; Kish et al., 2013).
Dyshomeostasis of microbiota is known to affect nutrition (Larsbrink et al., 2014; Flint
et al., 2012; Shreiner et al., 2015), host immunity (Flint et al., 2012; Shreiner et al.,
2015), and likely other health-related functions. However, direct evidence of PM2.5 re-
lated to intestinal micro-ecology-mediated neurodegenerative diseases has not yet been
available.
Although the exact mechanism(s) by which inflammatory responses initiated in
the respiratory or digestive system may affect the CNS are still unknown, potential
molecular mechanisms include neuroinflammation, oxidative stress, mitochondrial dys-
function, neuronal apoptosis and synaptic damage (Zhu et al., 2020). Evidence suggests
that pro-inflammatory cytokines derived from systemic inflammation can disrupt blood
brain barrier (BBB) integrity and increased BBB permeability, allowing the entry of
immune cells and pro-inflammatory cytokines into the brain (Zhu et al., 2020). In the
case of water-soluble PM2.5, particle decomposition in the nasal cavity, lower respira-
tory system, or GI track can produce smaller subparticles or soluble compounds that,
in addition to initiating localized adverse effects, can infiltrate the circulatory system
and directly damage other systems (Maher et al., 2016; Calderón-Garcidueñas et al.,
2008; Stone et al., 2017; Miller et al., 2017).
4.2 Future research directions
To date, epidemiological investigations of PM2.5 and neurodegenerative diseases have
covered a wide variety of geographical locations and populations. However, a number
of important questions remain unaddressed and new challenges have become apparent.
Below, we outline several challenges and opportunities for future research on PM2.5 and
neurodegeneration.
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Figure 4.1: PM2.5 routes of action include the upper (1) and lower (2) respiratory
system, and digestive system (3). PM2.5 can locally trigger inflammatory responses
that may extend to other systems including the CNS. Image from Offord (2019)
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Future studies
In Chapter 2 and 3 we assessed the potential association between PM2.5 exposure
and PD-aggravation at the population level, leveraging a state-wide administrative
dataset of hospital admissions. Studies using such data at the population level present
many advantages; they are easy to carry out, inexpensive, and provide much needed
statistical power when studying rare diseases such as ALS. Studies relying on adminis-
trative data can provide valuable information and are a good starting point; however,
these types of studies can be prone to certain biases and interpretation can occasionally
be challenging. Because they are commonly based on area-level analyses, care must be
taken when extrapolating results to the individual level — particularly for the inference
of causation. Thus, future studies at the individual-level or designed with a combination
of group- and individual-level data (Haneuse and Bartell, 2011) are critically important
to supplement our findings.
Valuable aspects to consider in future studies of the PM2.5–disease aggravation rela-
tionship include specific outcome measurements for disease aggravation and information
on patient comorbidities. In our studies, we used first hospitalization with a primary
or secondary disease diagnosis as a proxy for aggravation; however, this measurement
lacks specificity and may identify a non-disease related event as an aggravation episode.
Moreover, hospitalization data likely miss milder aggravation events, that is, those that
do not lead to a hospitalization, and are likely to capture only patients in more advanced
stages of the disease. A better outcome measurement for disease aggravation could be
disease scale scores. For instance, the Movement Disorder Society-Sponsored Revision
of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) is a comprehensive
assessment of both motor and non-motor symptoms used to monitor the burden and
extend of PD across the longitudinal disease course (Goetz et al., 2008). The MDS-
UPDRS is used by neurologist to follow the course of disease in a more objective manner
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and is the most common scale used in the clinical study of PD. Cut-off points to clas-
sify PD patients as mild, moderate, or severe on the basis of their MDS-UPDRS scores
have been proposed previously (Mart́ınez-Mart́ın et al., 2015). Examining the effects
PM2.5 exposure has on, for instance, time to reach the moderate or severe stage of dis-
ease from the date of clinical diagnosis would provide a better characterization of the
effect PM2.5 exposure has on disease aggravation and the overall disease progression.
Using a scale that includes both motor and non-motor assessments presents advantages
over other outcome measurements that exclusively assess neuronal loss, such as brain
imaging techniques, by providing a more holistic examination of the effects that air
pollution may have on PD patients. Another valuable piece of information to include
in future studies is information on comorbilities. In Chapter 2, we reported a stronger
association in PD patients <70 which indicates certain patient subpopulations may
be more vulnerable to exposure. Thus, including comorbidities in the analysis could
help identify characteristics of vulnerable patients and provide valuable information to
better understand the PM2.5–disease aggravation relationship and potential pathology
mechanisms.
In Figure 4.2, we propose a Directed Acyclic Dag (DAG) of the association between
PM2.5 and PD-aggravation for an individual-level analysis assuming residential-level ex-
posure. In the DAG, we include contextual factors and other important confounding
sources to be considered in future individual-level studies. In summary, we suggest
that age of disease onset and PD-associated genetic variants are factors that influence
disease exacerbation (Tysnes and Storstein, 2017; Elbaz et al., 2016; Poewe and Wen-
ning, 1998; Poewe, 2006), but not likely sources of confounding bias because they are
not associated with PM2.5 exposure. We included comorbidities as potential mediators
in the PM2.5–PD-aggravation causal path, since certain comorbidities, such as demen-
tia and depression, have been associated with a more rapid decline in PD patients
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(Bjornestad et al., 2017; Poewe, 2006) and exposure to PM2.5 has been identified as
a potential risk factor for some of these comorbidities (Salinas-Rodŕıguez et al., 2018;
Ailshire and Crimmins, 2014; Peters et al., 2019). However, if certain comorbidities
act as mediators 4.2, advanced modification-mediation decomposition methods may be
needed (VanderWeele, 2014). Lastly, we identified SES as a potential confounder. SES
is associated with both exposure to PM2.5 and likely with disease aggravation, since
patients with higher income have access to better health care, treatments, nursing facil-
ities, and overall a higher quality of life. Thus, SES is likely the most important source
of confounding that should be properly adjusted for in future analyses. Since most epi-
demiological studies assess exposure using model predictions at the residential address,
individual-level SES and other life-style and behavioral factors can only be correlated
to the predicted PM2.5 through neighborhood-level SES. That is, individual-level SES
cannot act as a confounder itself except through neighborhood-level SES (Weisskopf
and Webster, 2017). Thus, care must be taken to properly characterize and adjust for
neighborhood-level SES. Unfortunately, neighborhood-level SES is not a well-defined
construct. Occasionally, therefore, adjustment for individual-level SES and life-style
factors can help improve the adjustment for neighborhood-level SES.
Considering PM2.5 composition
A relevant aspect that we already introduced in Chapter 3 is the importance of
PM2.5 composition. Studies that assess exposure to PM2.5 generally evaluate the over-
all effect of exposure to the total PM2.5 mixture. In Chapter 3, we found that only
the nitrate and OM components of PM2.5 are associated with disease aggravation in
PD in New York State. Our results indicate that exposure to certain PM2.5 compo-
nents may pose higher risk than others — highlighting the need to expand research
on PM2.5 chemical composition. When analyzing PM2.5 as a mixture, is important
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Figure 4.2: Direct acyclic graph for an individual-level study with predicted PM2.5
exposures. The blue arrow represents potential source of confounding and the green
line a mediator path via comorbidities.
to consider the research question on hand and carefully select the statistical method
that best reflects the research question (Gibson et al., 2019). Some important research
questions to consider in the context of PM2.5 and neurodegenerative diseases include
whether PM2.5 components interact to produce a given adverse effect, whether PM2.5
components have additive effects with minimal individual toxicities, or if the overall
PM2.5 effect arises mainly from a single component or set of components. Altogether,
this information would facilitate comparison of results across studies from different ge-
ographical locations with different composition and provide useful information to help
identify source-specific mixtures (e.g. traffic vs. secondarily formed particles vs. coal
power plant emissions) that appear to be particularly toxic for a given outcome.
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Disease progression and aggravation
The average life expectancy post PD clinical diagnosis varies widely, ranging from
approximately 5 to 15 years (Poewe and Wenning, 1998; Poewe, 2006). However, little is
known about the environmental factors that influence differences in disease prognosis in
PD and other neurodegenerative diseases. This topic is becoming increasingly relevant
as the world population continues to grow older and the prevalence of neurodegenerative
diseases is projected to rise (He et al., 2016; Savica et al., 2016).
The link between PM2.5 exposure and neurodegenerative disease progression or ag-
gravation are important research questions with valuable implications for treatment
and disease management, but only few epidemiological studies have addressed these
questions (Kioumourtzoglou et al., 2015; Zanobetti et al., 2014; Lee et al., 2017). Up
to now, epidemiological studies have largely focused on disease risk, that is, whether
PM2.5 contributes to the development of the disease. Evaluating disease progression
would require outcome data at multiple time points throughout the course of the dis-
ease. As briefly mentioned above, in the Future Studies subsection, clinical scales of
disease severity or time from clinical diagnosis to death can be relevant outcomes to
study in the context of disease progression. In this dissertation, we examined the effect
of long-term PM2.5 exposure on disease aggravation using the first hospitalization as
a surrogate. Patients with neurodegenerative diseases are more likely to be hospital-
ized compared to older adults without neurodegenerative diseases (Nichols et al., 2019;
Association, 2019). Additionally, hospitalizations become more common as the disease
progresses and patients are usually discharged to nursing homes after the first hospi-
talization — 50% of hospitalizations occur in advanced stages of the disease (Oguh
and Videnovic, 2012; Albert et al., 1999; Lechtzin et al., 2001; Rudolph et al., 2010).
Altogether, this information indicates that the first hospitalization can be a relevant
surrogate to evaluate disease aggravation in neurodegenerative diseases. Moreover, hos-
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pitalization data can capture non-neurological health complications that may arise as
the neurodegenerative disease progresses. Lee et al. (2017) and Zanobetti et al. (2014)
evaluated short-term exposure to PM2.5 and disease aggravation in PD using hospi-
talization data — both found a positive association. In the studies presented on this
dissertation, we also found a positive association between long-term PM2.5 exposure
and disease aggravation in PD. These positive findings warrant further investigation
into whether PM2.5 exposure affects the course of disease and the identification of the
most relevant exposure windows. As we move forward in the study of PM2.5 exposure
and neurodegenerative diseases, it is important to also consider the role PM2.5 exposure
may play in disease prognosis and to explore suitable options to quantify this effect.
Windows of exposure in disease development
Assessment of long-term exposures is particularly relevant in the context of neu-
rodegenerative diseases, which are known to develop over the course of many years
prior to manifestation of overt clinical symptoms. Hence, an exposure assessment of
one or two years prior to clinical diagnosis of disease is likely to underestimate or
completely miss the contribution of PM2.5 to the development of the disease, if the
important windows of exposure are not considered. Multiple studies have used average
PM2.5 concentrations over 1-3 years (often post-diagnosis) and assume this exposure
level to be representative of an individual’s long-term PM2.5 exposure prior to clinical
diagnosis (Kirrane et al., 2015; Liu et al., 2016). However, this oversimplification of
the exposure paradigm eliminates important annual variability in PM2.5 concentrations
and temporal trends and is likely to result in large exposure measurement error. It is
important that future investigations into disease development consider longer windows
of exposure if data allow.
In part, the limitations of previous studies in regards to windows of exposure arise
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from limitations in exposure or outcome data. Traditionally, epidemiological studies
have used PM2.5 monitoring data for exposure assessments; however, PM2.5 was not
regulated in the US prior to 2000 and, therefore, we have no PM2.5 measurements before
that year. That is, we do not have data to assess early-life exposures for the people
being diagnosed now. Furthermore, the current US monitoring system mainly covers
populated urban sites, but large portions of rural and semi-urban regions do not have
any monitoring in place, limiting geographical representation in studies. Prediction
models, like the ones we used in our studies, fill in the geographical and temporal
sparsity of monitoring data and provide exposure information for larger regions that
include both urban and rural areas over a continuous number of years. Although PM2.5
estimates are for the most part also only available post year 2000 and, thus, do not
facilitate evaluation of early life exposures (childhood, early adulthood), these data
still present an opportunity to begin analyzing longer windows of exposure in larger
geographical regions. The second limitation, and likely the biggest impediment in
addressing longer windows of exposure, arises from limitations on patient data which
we discuss in more detail in the section below.
Medical registries
A major limitation in the study of environmental contributors to neurodegenera-
tive diseases is patient data availability. Although AD and PD are the most common
neurodegenerative diseases worldwide, they are still considered rare outcomes and large
sample sizes are required to precisely identify environmental contributing factors. In
the US, no medical registries currently exist that are spatially and temporally resolved
to allow for adequate exposure contrast in environmental health studies of neurode-
generative diseases. As a result, researchers have had to leverage information from
cohorts and registries that were not designed for the study of neurodegenerative dis-
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eases. Many of these cohorts contain information only about the year of clinical diag-
nosis. This presents a challenge in studying disease progression or aggravation, as these
cohorts do not provide information about stages of disease, mortality information post-
diagnosis, or medication usage. Furthermore, neurodegenerative diseases are known to
have a multifactorial etiology, where neither genetics or environmental exposures alone
are likely to cause disease. Rather, the disease is likely caused by interactions among
multiple factors. It is possible that PM2.5 exposure contributes to neurodegenerative
diseases only in a subset of patients that carry certain genetic predisposition or comor-
bidities. For instance, in Chapter 2, we estimated a significantly positive PM2.5 effect
among patients < 70 and no effect on those ≥70 years of age. Thus, having informa-
tion about whether a patient has a family history of disease or relevant comorbidities,
such as depression or dementia, would allow researchers to study the effects of PM2.5
exposure from a multifactorial prospective. Although developing a registry is certainly
a difficult task to tackle, with long-term challenges, having access to more information
on cases is crucial to fill in the gaps in knowledge of how PM2.5 might contribute to
neurodegenerative diseases.
4.3 Public health implications
Air pollution is the 4th leading cause of premature death globally, responsible for
4.2 million premature deaths in 2015 alone (Cohen et al., 2017). Air pollution is an
insufficiently appreciated cause of non-communicable diseases, responsible for 19% of
all cardiovascular deaths, 24% of ischaemic heart disease deaths, 21% of stroke deaths,
and 23% of lung cancer deaths, worldwide (WHO, 2014). Additionally, ambient air
pollution appears to be an important, although not yet explicitly quantified, risk factor
for neurodegenerative diseases. The studies presented in this dissertation aimed to
contribute to a better understanding of the link between PM2.5 exposure and clinical
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aggravation of neurodegenerative diseases.
The findings presented in this dissertation are particularly relevant, as the num-
ber of adults living with neurodegenerative diseases increases and negatively affects
families, communities, and health-care systems around the world (Savica et al., 2016;
Nichols et al., 2019). Hence, identifying factors that reduce the risk for or morbidity of
these conditions is imperative. Air pollution, albeit ubiquitous, is a modifiable exposure
and its association with disease aggravation in PD can have significant public health
implications. Confirming an association would inform the development of preventive
strategies to minimize exposure in individuals that have been diagnosed with PD. For
instance, if possible, diagnosed patients could avoid living in busy cities or next to ma-
jor highways, and simpler strategies could involve using indoor air filters, or face masks
when outdoors. As of now, there is no cure or treatment for neurodegenerative diseases;
thus, implementation of strategies to reduce or prevent exposure to contributing envi-
ronmental factors could have a significant impact on a larger scale. Most importantly,
confirming an association between PM2.5 exposure and PD disease aggravation would
provide leverage to demand stricter government regulations and actions to decrease air
pollution levels. In Chapter 2, we observed that the total PM2.5–PD association has a
steeper slope at lower concentrations that are well below the current annual NAAQS for
PM2.5, indicating that current standards do not safeguard the population’s neurological
health.
There has been a significant amount of progress on decreasing air pollution levels
in the US since the air pollution episode that New Yorkers experienced during the
Thanksgiving of 1966. However, as the country with the highest gross domestic product
worldwide, the US has the resources to do much more in ensuring that we all have access
to clean air, particularly as we continue to learn about the many adverse health effects
associated with exposure to air pollution.
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Amyotrophic lateral sclerosis (ALS) is an adult-onset paralytic disorder, usually
fatal within 1-5 years post clinical onset. Most previous ALS gene-environment in-
teraction (G×E) studies have used animal models with a full-blown ALS phenotype
and environmental exposures already significantly neurotoxic by themselves question-
ing whether G×E was actually studied. ALS patients do not generally present signs
of neurotoxicity before showing clinical ALS symptoms, which suggests that G×E in
ALS likely results from the interaction between silent toxicities and silent genetic sus-
ceptibilities. Therefore, we used a knock-in mouse model of an incompletely penetrant
variant of TDP-43, “G298S”, to model this hypothesis. The heterozygous (G298S-het)
knock-in mice do not present ALS pathology over their lifespan but the homozygous
knock-in show mild neuromuscular junction denervation at an advanced age (2.5 years),
confirming the validity of the these knock-in mice as ALS models. Searching for neu-
rotoxic exposures compatible with being a risk factor for ALS, we found manganese
(Mn) as a compelling candidate. Excessive Mn exposure causes manganism, which
resembles Parkinson’s disease but it also causes ALS-like symptoms (e.g. muscle weak-
ness) and lesions (corticospinal tract degeneration). Additionally, elevated Mn levels
have been detected in the spinal cord of ALS patients and animal models. In this
study, we exposed wild-type (WT) and G298S-het mice to 200ppm manganese chloride
(MnCl2) via drinking water ad libitum for seven months starting in young adulthood.
Humans are rarely expose to this high level of Mn water, but this is one of the lowest
levels use in a mouse study. Mn-exposed and non-exposed mice were tested weekly
by treatment/genotype-blinded investigators either for grip strength (loaded grid) or
general locomotor activity (rotarod) over the whole study period. At the end of the
study, mice were also tested for gait (CatWalkTM), locomotor activity and exploratory
behavior (openfield), memory (novel object recognition test), and anxiety-related be-
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havior (elevated plus maze). In the motor test performed longitudinally, we found not
deficits in performance as a result of Mn exposure. We also observed not statistically
significant differences on cognition or anxiety related behaviors across any group. How-
ever, WT mice showed significantly higher locomotor levels compared to non-exposed
WT but this effect was not observed in the G298S-het. We also found differential effects
of exposure by genotype on exploratory behavior. Additionally, we observed increased
rearing activity and gait-related differences in G298S-het mice relative to WT most of
the time independent of Mn exposure. Metal measurement analyses are currently on-
going to determine if the exposure level used (200ppm) lead to a significant increase of
Mn concentration in the central nervous system (CNS) or other tissues. Additionally,
pathological analysis will be carried out to confirm whether prodromal signs of ALS
such as neuromuscular junction denervation or CNS gliosis can be detected. Altogether,
our studies suggest that higher concentrations of Mn or different windows of exposure
should be tested to determine whether Mn-environment interaction may have a role in
ALS onset or disease progression.
A.2 Introduction
ALS is an adult-onset motor neuron (MN) disorder with an incidence of 1-2/100,000
characterized by progressive paralysis due to degeneration of spinal and cortical MNs
(Saberi et al., 2015; Hirano, 1996). The predominantly sporadic nature of ALS (90% of
cases) and the intra- and inter-family variability in disease progression and age at onset
(Renton et al., 2014; Kirby et al., 2010) indicate ALS is a multi-factorial disease likely
resulting from the concomitance of genetic predisposition and environmental factors
(Al-Chalabi and Hardiman, 2013; Hardiman et al., 2017). Several toxicants have been
linked with ALS such as metals, the algal toxin beta-methylamino alanine (BMAA),
and pesticides (Al-Chalabi and Hardiman, 2013; Hardiman et al., 2017). However, no
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environmental exposure has been confirmed to contribute to the disease, possibly due to
the lack of study models that assess genetic and environmental factors simultaneously.
Since, patients do not generally report signs of neurotoxicity before developing ALS,
we hypothesize that G×E in ALS likely results from the interaction between silent
exposures and silent genetic susceptibilities. Thus, the objective of this study was to
try to develop such an animal model of genuine G×E in ALS.
Transgenic (Tg) mouse models of familial ALS, such as the mutant superoxide dis-
mutase 1 (SOD1) model, have confirmed the feasibility of closely emulating ALS in
mice (Gurney et al., 1994), but animal studies on the environmental contributors to
ALS are sparse. Past works have either exposed WT animals to high concentrations
of neurotoxicants with overt toxicities (Arvidson, 1992; Estevez et al., 2012), or ex-
posed the already full-blown SOD1 mice to lower levels of neurotoxicants (Groeneveld
et al., 2003; Barbeito et al., 2010). However, there is not animal studies modeling the
interaction between genetic susceptibilities to ALS and mild environmental exposures,
primarily because animal models of genetic susceptibilities to ALS are lacking. As TDP-
43 protein aggregates and inclusions have been associated with the ALS-frontotemporal
dementia complex and observed in the CNS tissue of the vast majority of ALS patients
(Ferrari et al., 2011; Liscic et al., 2008), many groups tried to develop Tg TDP-43 mice
models. However, no TDP-43 mice modeled ALS as well as the SOD1 mice — most
TDP-43 models had no or mild phenotypes (McGoldrick et al., 2013). For our study,
we took advantage of one of this such models to study G×E in ALS. We used a ge-
netic knock-in mouse model carrying the ALS-associated genetic variant G298S in the
TDP-43 gene (Kirby et al., 2010; Ebstein et al., 2019). The G298S-het knock-in was
characterized as ALS asymptomatic and free of MN pathology whereas the homozy-
gous showed mild neuromuscular denervation in late age stages (Ebstein et al., 2019) —
indicating a potential gene-dose effect. This model not only recapitulates endogenous
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levels of the mutant TDP-43 as we see in humans, but also the variant G298S has a
reported incomplete segregation with phenotype (Harms and Baloh, 2013), providing
us with an animal model of genetic susceptibility to ALS.
Searching for neurotoxic exposures relevant to ALS and that we could test in this
ALS-silent animal model, we hypothesized that the neurotoxic metal Mn could be a
particularly compelling candidate based on the following. Mn is a trace element vital to
human health as a cofactor for a variety of enzymes, critical to metabolism and redox
homeostasis (Smith et al., 2017). However, excessive exposure to Mn can result in accu-
mulation of the metal in the brain and a severe motor disorder resembling Parkinson’s
disease and referred to as manganism (Guilarte, 2011; Smith et al., 2017). Clinical
observations of workers exposed to excessive levels of Mn include impaired fine-motor
control, hyperreflexia and muscle weakness (Racette, 2014), which are characteristics
of corticospinal impairment as seen in ALS (Bouchard et al., 2007; Ross, 2016; Mena
et al., 1967). Non-motor symptoms such as anxiety and other psychiatric symptoms
are also induce by manganese toxicity (Racette, 2014). Based on this array of clinical
signs, elevated Mn has been suspected to drive the high prevalence of ALS-Parkinson
dementia complex in Guam and the Kii Peninsula of Japan (Bowman et al., 2011; Iwami
et al., 1993). Additionally, cases of Mn miners and smelters developing ALS have been
reported (Penalver et al., 1957; Yanagihara, 1982). Corticospinal impairments have also
been detected in neuroimaging studies among users of ephedrone, which is a home-made
drug containing high levels of Mn (Stepens et al., 2010). Mouse and primate-based ex-
posure studies also indicate that Mn neurotoxicity is mainly observed in the globus
pallidus, the striatum, and the frontal cortex (Guilarte et al., 2008; Chen et al., 2002).
Elevated Mn levels were also detected in the spinal cord of ALS patients but in pa-
tients’ body fluids and other peripheral biospecimens such as hair, the findings have
been both negative and positive (Roos, 2017; Bergomi et al., 2002; Hozumi et al., 2011;
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Garzillo et al., 2014; Bocca et al., 2015; Peters et al., 2016). Given these evidences, we
investigated the potential contribution of Mn exposure to ALS clinical disease onset.
We hypothesized that low-level Mn exposures, sub-toxic for the general population,
potentially interact with ALS-linked genetic susceptibilities to influence ALS disease
expression. To test our hypothesis, we exposed G298S-het knock-in mice to Mn via
drinking water — a route of exposure relevant to most people. Our objective is to
determine whether a long-term low stressor may trigger the onset of ALS pathology
in our ”ALS silent” animal model. We maintained the exposure for a period of seven
months, one of the longest exposure study ever performed. As we are interested in
modeling G×E, we selected Mn concentrations that alone should not have pronounced
neurotoxicity on WT subjects. In our study, in addition to motor assays that evaluate
ALS related symptoms, we included behavioral tests previously shown to be impacted
by Mn exposure to evaluate any non-ALS but Mn-related neurotoxicities. Altogether,
through this study we aimed at gaining insight into potential gene-metal interaction in
ALS by using a relevant model of genetic susceptibility to ALS and low-level exposures
to Mn via the oral route.
A.3 Methods
Animals and exposure paradigm
All animals were housed on a 12 hours light/dark cycle in a temperature-controlled
room (maintained at 22 to 24 ◦C) and had access to standard chow ad libitum. All
animal work described in this study was reviewed and approved by the Columbia Uni-
versity Institutional Animal Care and Use Committee (IACUC) prior to starting any
experiments. All in vivo procedures (e.g. Mn exposure and behavioral testing) were
described in an IACUC protocol. All studies used mice on a C57BL/6J background,
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a classical strain for neurotoxicity studies (Jiao et al., 2012). The G298S-het knock-in
mice on a C57BL/6J strain background were obtained from the Neil Schneider labo-
ratory. The design and characterization of the knock-in model is described in Ebstein
et al. (2019). The WT C57BL/6J mice were purchased from Jackson Laboratory. To
control for sex, our study included 50% females and 50% males. Mice were distributed
in four groups by genotype: G298S-het or WT; and treatment: control water or Mn
treated water (total n = 24, with 6 mice/group; A.1). Control groups were exposed
to vehicle (sterilized tap water) while the Mn group was exposed to 200ppm MnCl2
for seven months via drinking water ad libitum. MnCl2 was purchased from Sigma-
Aldrich in solid form at >99% purity. The 200ppm MnCl2 concentration was chosen
to remain below the lowest Mn concentration previously reported to have neurotoxic
effects in adult WT mice through the oral route (400ppm) (Krishna et al., 2014). We
anticipated that exposure to 200ppm MnCl2 water would increase the total Mn intake
of a mouse by approximately three fold as compared to non-exposed groups. The cal-
culation was based on the Mn present in the PicoLab rodent diet 20 chow (85 ppm), a
4.8 mg/day average food intake and a 5 mL/day average water intake of a ∼25 grams
C57BL/6J mouse (Bachmanov et al., 2002). From food, we calculated a Mn aver-
age consumption of 17 mg/kg/day and from the 200ppm Mn-supplemented water 40
mg/kg/day, that is, a total of ∼57 mg/kg/day for the Mn-exposed groups (3.3× above
non-exposed groups [17 mg/kg/day]). Exposure started in young adult animals that
were on average 5 months of age when treatment began. The MnCl2 solutions were
freshly prepared and renewed weekly. To monitor the level of exposure throughout the
study, body weight and water intake were recorded weekly. Animals were housed in
triplets and all animals within a cage were either in the treatment or control group.
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Figure A.1: Study design of in vivo exposure to MnCl2 via drinking water.
Mice were 5-months old in the beginning of the exposure and nearly 1 year old in the
end of the study. Males and females were equally balanced in all groups.
Behavior assays
The behavioral tests chosen have been used extensively in rodents as measures of
locomotor, cognitive and emotional function (Alfieri et al., 2016, 2014; Ke et al., 2015),
alteration of which is common in Mn-exposed humans (Oulhote et al., 2014; Bouchard
et al., 2007; Bowler et al., 2012; Krishna et al., 2014). The loaded grid test has been
used extensively in ALS as a proxy for early stage muscle denervation (Barnéoud et al.,
1997) and the rotarod test is usually used to characterize general motor deficit and loss
of coordination as disease progresses (Oliván et al., 2014). The open field, rotarod and
elevated plus maze have also documented behavioral impairments in rodents exposed
to Mn via different routes (Cordova et al., 2013; Dodd et al., 2005; Toro et al., 2019).
The CatWalk XT apparatus collects gait information on multiple parameters relevant
to ALS and allows to discriminate between hindlimb and forelimb, as well as between
left and right paw deficits — this is important to characterize ALS mouse models as
hindlimb deficits are reported before forelimb ones, and deficits start in an asymmetric
manner (Wijesekera and Leigh, 2009). All animals were naive to behavioral appara-
tuses prior to initiation of testing and all tests were performed in a behavioral testing
designated room located nearby but separate from that in which animals were housed
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with the experimenter blinded to the animal treatment and genotype.
Loaded Grid: This test was performed using a set of four grids with increasing
weights: 10, 20, 30, and 40 grams. Before Mn exposure started, mice were trained to
hold the weight, first with the lowest grid and including an additional grid every week
(4 weeks total training period). During a test session, animals were hold by the tail
and allow to hold the weighted grid with their limbs. Each animal was allowed to hold
each weighted grid for up to 30 seconds and given 3 trials per grid starting with the
lowest weighted grid. After each trial, the animal was given a 15-seconds break and
a 30-seconds break after the third trial, before moving onto the next heavier weighted
grid. The best time score for each weight was recorded and then a net score sum was
calculated by first multiplying the best scored time (seconds) in each weighted grid by
the weight (grams) (score = Best time × 10 + Best time × 20 + Best time × 30 + Best
time × 40), so that the score ranges from 0 to 3,000. The loaded grid was performed
weekly for 4 months starting 3 months prior to treatment, then biweekly for 5 months
and stopped 1 month prior to animal sacrificing (Figure A.2).
Rotarod Balance and coordination performance of the mice was determined using
a Rotarod (Ugo Basile, model 7600) in constant acceleration mode (2.5 rpm/s from
5–60 rpm) over 120 seconds (Alfieri et al., 2014). Before starting to record data, mice
were trained for 2 weeks to the apparatus. Two trials were carried out during a test day,
with a one minute interval rest between trials. The longest time each mouse remained
on the turning wheel (i.e. latency to fall in seconds) out of the two trials per session
was recorded. This test was performed biweekly for 5 months beginning one month
post treatment and discontinued one month prior to animal sacrifice (Figure A.2).
CatWalk: CatWalk XT is an automated test for gait functions and locomotion. It
is used to phenotype mouse models of neurodegenerative diseases including ALS. The
Catwalk apparatus (Noldus Information Technology, Leesbug, VA) consists of an illu-
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minated walled glass walkway (130 cm × 10 cm) and a high-speed camera underneath.
The mouse is placed at the start location and allowed to ambulate freely across the
runway toward the goal box at the end of the walkway. Light is reflected and illumi-
nates the stimulus (footprint) when downward pressure is applied. Walking patterns
are captured with a high-speed camera mounted underneath the walkway. The mouse
is allowed to traverse the walkway as many times as needed to obtain at least 3 flu-
ent crossings (without stopping or hesitations). Parameters automatically collected by
the software include stride length, width, base of support, distance between ipsilateral
prints, cadence, support formulas, step sequence, phase lags, and walking speed. At
the end of the test, the mouse is returned to its home cage. The walkway is cleaned
with paper towel moistened with 70% ethanol and wiped dry between trials. This test
was performed once during the last month of the 7-months exposure (Figure A.2).
Open field: This test is often used to detect if a certain compound produces hyper-
or hypo-locomotor effects or modulates mouse exploratory behavior (i.e. time in the
center of the field versus periphery). Assessment of general exploration and locomotion
in a novel environment was performed as previously described (Alfieri et al., 2014).
Mice were placed in a clear Plexiglas (40cm × 40cm × 40cm) arena (one mouse per
arena) with floor divided into two zones: periphery and center (comprising 50% of the
total area centered). Total horizontal activity, exploratory behavior in the center zone,
and vertical locomotor activity were assessed for a 1-hour period; illumination was kept
at 30 lux. Total and center distance traveled by the mice was quantified as well as
vertical movement (rearing). This test was performed once during the last month of
the 7-months exposure (Figure A.2).
Elevated plus maze: This classic test for anxiety-like behavior is based on rodents’
innate fear for height and open space. The elevated plus-maze consists of two open arms
(30cm × 5cm) and two closed arms (30 × 5 × 15 cm) extending from a central area
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(5 × 5 cm). Photo beams embedded at arm entrances register movements. Mice were
placed in the center, facing a closed arm. The mouse was allowed to freely explore the
maze for 5 minutes. Time spent in the open arm and closed arm were automatically
scored by the MED-PC V 64bit Software (Med Associates). Room illumination was
approximately 30 lux. This test was performed once during the last month of the
7-month exposure (Figure A.2).
Noval object recognition test: This test is used to measure an animals’ abil-
ity to differentiate a novel object from a familiar object — behavioral readouts for
explicit memory and spatial memory. This test has previously been used to evaluate
memory in animal models of ALS-frontotemporal dementia (Wong et al., 2020). The
test was conducted in a clean white rectangular arena ([40 cm × 40 cm], Instrument
Shop, Vanderbilt Clinic, CUMC). The animal was allowed to habituate to the arena
for 30 minutes, then briefly removed from the arena while the experimenter placed two
identical objects (rectangular shaped plastic toys about 2.5” tall) in the arena. The
mouse was then returned to the arena and allowed to freely explore the two objects for
10 minutes (familiarization), then removed from the arena. An hour after the famil-
iarization session, the mouse was returned to the arena for a 5-minutes memory test.
For the memory test, one of the objects used in the familiarization session is replaced
with a novel object (new shaped object). Time spent sniffing each object was analyzed
from recorded videos using automated software. The exploration time represents the
percentage of time that mice spent exploring the object (familiar or novel) respective
to the total exploration time (familiar + novel), as previously described (Alfieri et al.,
2014). Recognition memory is defined as spending significantly more time sniffing the
novel object than the familiar object. Failing to show preference for the novel object is
interpreted as a memory deficit. This test was performed once during the last month
of the 7-months exposure (Figure A.2).
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Figure A.2: Behavior tests and manganese exposure timeline. Mos = months,
refers to the animals age at the respective time points.
Statistical analysis
All analysis was done using the statistical software R, version 3.6.2. To evaluate
the loaded grid and rotarod data, we used linear mixed models which account for the
longitudinality of the data; these two models also included an interaction term for
genotype. For all the other behavior test, we used ANOVA to test differences across
genotype and exposure groups follow up with a Tukey pairwise test adjusted for multiple
comparisons.
A.4 Results
Animal water consumption and weight
As illustrated by our longitudinal data of water consumption monitoring (Figure
A.3), the addition of 200 ppm MnCl2in drinking water did not decrease the overall water
consumption of the mice. While overall older mice showed a tendency to decrease their
water intake, no significant differences were observed between groups. As compared to
our theoretical calculation in section A.3, the concentration of 200 ppm MnCl2given
via drinking water resulted in an average Mn daily intake of 30 mg/kg/day (instead of
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40 mg/kg/day predicted) based on an observed ∼0.15 ml/g average water intake (4.5
ml for a 30 g mouse) (Figure A.3). Therefore, in addition to food (assumed to be 17
mg/kg/day) Mn exposure via drinking water increased the Mn net consumption to 47
mg/kg/day — approximately 3× the average rodent daily Mn intake.
Overall, independently of their treatment and genotype, all mice appeared healthy
throughout the exposure time. Mice were active, their weight increased at a normal
rate within this age range (Bachmanov et al., 2002) and we did not observe any signif-
icant weight loss (Figure A.3), which indicates that mice did not develop a paralytic
phenotype given that weight loss is often used as a correlate of paralysis onset in ALS
mouse models (Vinsant et al., 2013). In the end of the study, WT mice had an average
lower weight than G298S-het mice but this difference was not significant. Altogether,
chronic exposure to 200ppm MnCl2 for 7 months via drinking water did not elicit any
signs of generic toxicity or any full blown ALS paralytic phenotype in any experimental
groups.
Assessment of motor function
We found a significant differences in grip strength between WT and G298S-het
subjects in absence of exposure i.e. in control conditions (P>0.001). The non-exposed
G298S-het show a mild but progressive deficit in grip strength that reached about 25%
at the end of the exposure study. In contrast, as illustrated in Figure A.4A, MnCl2
exposure did not have any significant adverse effect on grip strength on WT mice
but surprisingly it reversed the mild deficit observed in non-exposed G298S-het. As a
result, grip strength across exposure groups was not significantly different (P>0.05).
We did not observe any signs that Mn interact with G298S to trigger decrease in muscle
strength. Likewise, with the rotarod assay that was also performed longitudinally, we
did not find significant differences in motor performance and coordination across groups
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Figure A.3: Water consumption and animal weight. A. Slight decrease in water
consumption around week 10 of exposure was observed but not significant difference
was observed across groups (P>0.05). B. Consistent weight increase over time and
not significant differences in weight across groups (P>0.05). Points show individual
data points and the solid line is a smoother line to facilitate visualization of the overall
pattern.
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(P>0.05). Overall, the latency to fall decrease overtime for all animals (Figure A.4B).
In the case of the CatWalk test, most of the parameters that we found to be sig-
nificantly different were affected on a genotype dependent manner. For instance, as
illustrated in Figure A.5, the max contact max intensity (indicates the largest part
of paw that contacts the ground), the print intensity, and the swing speed (ratio of
stride length to swing duration) were all found to be slightly increased in G298S-het
hindlimbs independently of Mn treatment. Similarly, slight but significant alterations
in paw print area (increased) and single stance (decreased) were found in G298S-het
mice (not shown). Altogether, these results suggest G298S-het may have some very
mild hindlimb deficits. Only few parameters show differences in gene-metal interaction
dependent manner. For instance, the print position (distance between placement of
front and hind paws over one step) was found to be selectively decreased in Mn-treated
G298S-het left paws with the same tendency in the right paws but genotype-dependent
A.5. This decrease in relative print positions may be suggestive of altered sensorimotor
status and reduced limb coordination.
Anxiety and hyperactivity
In the open field test, we observed significant increase in overall activity levels
(ambulatory distance recorded) in the Mn-exposed WT subjects relative to the non-
exposed WT group (P>0.001); however, this Mn effect was not observed among the
G298S-het subjects (Figure A.6A). Mn exposure also had different effects in WT vs.
G298S-het subjects in exploratory behavior. In non-exposed conditions, we did not
observe significant differences in the amount of time spend in the center (exploratory
behavior) across genotype groups, but Mn-exposed G298S-het mice spent less time in
the center relative to Mn-exposed WT, P<0.001 (Figure A.6B) — suggestive of G×E. In
regards to rearing, which is measure by vertical counts and an assessment of exploratory
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Figure A.4: Loaded grid and rotarod. Figure A. shows not significant difference
in grip strength between the Mn-exposed and non-exposed WT (left), and not signif-
icant differences between Mn-exposed G298S-het and non-exposed G298S-het (right).
Figure B. Shows not significant differences in balanced and coordination in exposed
vs. non-exposed groups as evaluated by the latency to fall in the rotarod test. Solid
lines show average trend, gray area represents 95% confidence intervals (CI) and points
correspond to individual data points. Red dashed line indicates beginning of treatment
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Figure A.5: CatWalk. Figure A-C. significant increases were identified in max con-
tact max intensity, paw print length and swing speed in a genotype-dependent manner;
Figure D significant decrease in print position were identified as a G×E for left paw
and based on genotype for right paw.
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behavior, we found significant differences across genotypes regardless of exposure with
higher rearing among the G298S-het, P>0.001 (Figure A.6C). To evaluate any potential
anxiety phenotypes, we tested the cohort in the elevated plus maze assay. However,
we did not observe any significant differences in the amount of time spent exploring
the open arm of the elevated maze neither across exposure or genotype groups, P>0.05
(Figure A.6D).
Memory functions
As TDP-43 mutations can either lead to ALS, FTD or both, we also assessed the
memory of our mice by the novel object recognition test. However, we did not observe
any significant differences in the percentage of time spent with the novel object neither
across exposure or genotype groups, P> 0.05 (not shown).
A.5 Discussion
To study potential G×E interactions in ALS, we used a heterozygous knock-in mouse
model carrying the imcompletely penetrant ALS-associated genetic variant G298S in
the TDP-43 gene. This animal model, which does not present any ALS typical pathol-
ogy in basal conditions (Ebstein et al., 2019), was exposed to relatively low levels of
MnCl2 (200ppm) via drinking water for a period of 7 months. The purpose of this study
was to evaluate in vivo whether Mn exposure at levels that have not neurotoxic effects
on WT mice can trigger the clinical onset of ALS in mice carrying an ALS-associated
genetic vulnerability. In contrast with our original hypothesis, no major behavioral
deficit and no conversion to an ALS paralytic phenotype was observed as a result of
Mn exposure. Only mild gait-related motor differences and decrease in some aspects of
exploratory behavior were measured to be significant in Mn-exposed G298S-het mice
relative to non-exposed group. However, we saw some differences across genotype in-
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Figure A.6: Open field and elevated plus maze. Fig. A-C show the results from
the open field test and Fig. D the elevated plus maze results. A. Significant increase
in total mobility in the Mn-exposed WT but not effect on G298S-het. B. G298S-het
Mn-exposed spent less time in center than WT Mn-exposed; effects of MnCl2 exposure
differ by genotype. C. Significant differences in rearing activity (vertical counts) across
genotype independently of exposure. D. No differences in percent of time spend on the
open arm of the elevated maze. Bars represent 95% CI. ** P<0.001
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dependent of exposure and evidence of potential G×E in non-ALS related behaviors.
Before to definitely conclude on the potential role of Mn in influencing ALS onset and
progression, more work will need to be done but several factors will need to be taken
into consideration in future studies.
Exposure Paradigm
Gavage is most common via of oral administration in in vivo Mn exposure studies
(Williams et al., 2012); these methods deliver a high concentration of Mn directly
into the stomach in a single dose (Turner et al., 2011). Here, we used continuous
administration of Mn via drinking water ad libitum to have an exposure paradigm more
relevant to human exposure (Hu et al., 2019; Kullar et al., 2019; Frisbie et al., 2012;
Hafeman et al., 2007; Kawamura et al., 1941). However, our exposure paradigm may
have resulted in a less efficient delivery of Mn as compared to a larger concentration
given daily at once (measurement of Mn concentration in CNS is still ongoing, see
Section A.6). As our objective was to expose the mice to a dose of Mn that will
not be neurotoxic to control WT mice, and given the limited number of studies that
use this route of administration in adult mice (Calabresi et al., 2001; Krishna et al.,
2014), we determined our dose based on a single study wherein Mn accumulation in
the brain and neurological effects were observed in WT mice exposed to 400ppm Mn
via drinking (Krishna et al., 2014). Specifically, in this study the authors reported
the development of gliosis in the brain of exposed mice as well as the development of
a significant decrease in grip strength. Therefore, to make ensure we will work with
a silent exposure paradigm and remain below neurotoxic concentrations for WT, we
reduced the concentration to 200ppm MnCl2. With this concentration of exposure,
as detailed in Section A.4, we theoretically increased the Mn intake of the mice by
3-fold to reach ∼46 mg/kg/day. Another study uses similar exposure concentrations
126
(i.e., 25 or 50 mg/kg/day via drinking water). However, in this study exposure started
early postnatally, at a time at which first pass metabolism mechanisms to limit Mn
intake in mice are not developed which may had resulted in a much higher uptake
of Mn. Altogether, our data suggest that testing long-term exposure at higher levels
than 200ppm or via different routes or paradigms could prove useful before definitely
concluding on the potential of Mn to have a role in the G×E influencing on ALS onset
or disease progression.
Is Mn protective?
Our behavior assessment results indicate that a 7-months exposure to 200ppm
MnCl2via drinking water had not major effects on cognitive, or anxiety-related behav-
iors either in WT or ALS-predisposed rodents. However, we observed a hyper-locomotor
behavior in Mn-exposed WT, as indicated by the open field test (Figure A.6). These
findings are similar to the findings reported for higher levels of Mn exposure in previous
studies (Krishna et al., 2014; Alfieri et al., 2016, 2014; Ke et al., 2015). Interestingly,
we did not see the same effect on the G298S-het whose net activity level was unaffected
by Mn exposure. Mn also appeared to have a differential effect on the amount of time
animals spend exploring the center area in the open field, which resulted in Mn-exposed
G298S spending significantly less amount of time exploring the center than Mn-exposed
WT (Figure A.6). This G×E effect was also observed in the loaded grid test where a
mild deficit in grip strength in non-exposed G298S-het mice was reverse by Mn expo-
sure but the exposure had not effect on WT (Figure A.4). In summary, we found some
G×E effects but some of our results indicate it can be an interaction that leads to a
protective effect rather than a toxic one as we originally hypothesized. Similar neu-
roprotective effects of Mn have been published in the context of Huntington’s disease
(Williams et al., 2010), another adult onset neurodegenerative disease. Given than Mn
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is also an essential nutrient, a hypothesis we formulated is that a Mn deficiency in the
G298S-het could be the cause of the protective effect we see and also explain why for
some tests we see effects of exposure in the WT but not in the G298S-het. Once we
complete the quantitative analysis of Mn concentration in tissue we would have more
information about the likelihood of this hypothesis.
ALS as an “early developmental” or “multiple hits”
determined disease?
Finally, one aspect we should consider in our failure to model a G×E ALS phenotype
could be the window of exposure we selected i.e. adult onset exposure. A leading hy-
pothesis for other neurodegenerative diseases like Parkinson’s and Alzheimer’s diseases
is “the developmental origin of health and disease” Faa et al. (2014); Hare et al. (2015);
Seifan et al. (2015); Tartaglione et al. (2015). This hypothesis considers perinatal ex-
posures are instrumental in the etiology of adult-onset disorders (Tartaglione et al.,
2015), possibly in association with “multiple-hits” across the life course. In Figueroa-
Romero et al. (2020) the authors proposed that early life metal dysregulation could
be instrumental in ALS. Specifically, this study provided evidence that altered metal
uptake during specific early life time windows is associated with adult-onset ALS in
both human (teeth biomarker) and an ALS mouse model (teeth and brain biomarkers).
A few epidemiological studies have also suggested a role of early-life exposure in ALS
(Ajdacic-Gross et al., 1998; Pamphlett and Fang, 2012; Fang et al., 2008). Therefore,
future experimental animal studies should investigate the impact of early life excessive
exposure to metals in the context of ALS.
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Not enough power to detect subtle effects?
In addition to differences in response to Mn exposure, there appeared to be underly-
ing mild differences by genotype, independent of exposure, in loaded grid performance,
gait, and vertical movement. The analysis of neuromuscular junction in the G298S-
het by Ebstein et al. (2019) revealed no signs of MN denervation, thus, these baseline
differences by genotype could result from non-MN related pathology which was not
evaluated by Ebstein et al. (2019). These differences could also be background noise.
Animal behavior tests have an intrinsic level of variability and it is likely that our cohort
size was not big enough to surpass this variance. This could be particularly influential
in studies evaluating a subtle phenotype.
A.6 Future steps
As previously mentioned, the thorough pathological analysis of our mice remains to
be performed. In particular, the investigation of neuromuscular junction denervation.
ALS is characterized by degeneration of MNs which leads to muscular denervation
and eventually MN cell death (Hardiman et al., 2017). Research suggests that cell
pathology in ALS is likely to begin years before clinical motor deficits manifest (clinical
pathology) (Al-Chalabi and Hardiman, 2013; Hardiman et al., 2017). It is possible that
the exposure duration of our study was not long enough for clinical motor deficits to
manifest, thus, an important next step is to confirm the integrity of the neuromuscular
junctions. As mentioned in Section A.5, another important next step is to confirm
whether our exposure level (200ppm MnCl2) actually lead to a significant increased in
Mn absorption. As part of this study, we collected the liver, spinal cord, brain, and
blood to measure Mn concentrations. The brain was snap frozen and section for spatial
measurement of Mn by laser ablation inductively coupled plasma mass spectrometry.
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Metal measurement analyses are currently ongoing in the laboratory of one of our col-
laborators and will confirm whether this level of Mn exposure increases concentrations
of Mn in the CNS. Confirming an increased Mn concentration internally is a crucial
next step in this study.
A.7 Conclusion
Studying long-term exposure to Mn at low-level concentrations that are relevant
to population exposures comes with challenges. Identifying an appropriate exposure
concentration that is strong enough to elicit an effect in vivo but not overly toxic
to allow for meaningful evaluation of G×E is a challenge in studying environmental
contributors to neurodegenerative diseases. Using drinking water ad libitum as the
route of exposure is highly relevant to population exposure but does not allow for a
precise administration. Altogether the preliminary findings of this study indicate that
exposure to 200ppm MnCl2 via drinking water is not enough to elicit ALS pathology
in a genetically predispose ALS animal model.
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Barnéoud, P., Lolivier, J., Sanger, D. J., Scatton, B., and Moser, P. (1997). Quantitative
motor assessment in fals mice: a longitudinal study. Neuroreport, 8(13):2861–2865.
Bergomi, M., Vinceti, M., Nacci, G., Pietrini, V., Brätter, P., Alber, D., Ferrari, A.,
Vescovi, L., Guidetti, D., Sola, P., et al. (2002). Environmental exposure to trace
elements and risk of amyotrophic lateral sclerosis: a population-based case–control
study. Environmental research, 89(2):116–123.
Bocca, B., Forte, G., Oggiano, R., Clemente, S., Asara, Y., Peruzzu, A., Farace, C.,
Pala, S., Fois, A. G., Pirina, P., et al. (2015). Level of neurotoxic metals in amy-
otrophic lateral sclerosis: a population-based case–control study. Journal of the
neurological sciences, 359(1-2):11–17.
Bouchard, M., Mergler, D., Baldwin, M., Panisset, M., Bowler, R., and Roels, H. (2007).
Neurobehavioral functioning after cessation of manganese exposure: A follow-up after
14 years. American journal of industrial medicine, 50(11):831–840.
131
Bowler, R. M., Harris, M., Gocheva, V., Wilson, K., Kim, Y., Davis, S. I., Bollweg,
G., Lobdell, D. T., Ngo, L., and Roels, H. A. (2012). Anxiety affecting parkinsonian
outcome and motor efficiency in adults of an ohio community with environmental
airborne manganese exposure. International journal of hygiene and environmental
health, 215(3):393–405.
Bowman, A. B., Kwakye, G. F., Hernández, E. H., and Aschner, M. (2011). Role of
manganese in neurodegenerative diseases. Journal of Trace Elements in Medicine
and Biology, 25(4):191–203.
Calabresi, P., Ammassari-Teule, M., Gubellini, P., Sancesario, G., Morello, M., Cen-
tonze, D., Marfia, G. A., Saulle, E., Passino, E., Picconi, B., et al. (2001). A synaptic
mechanism underlying the behavioral abnormalities induced by manganese intoxica-
tion. Neurobiology of disease, 8(3):419–432.
Chen, M.-T., Yiin, S.-J., Sheu, J.-Y., and Huang, Y.-L. (2002). Brain lipid peroxidation
and changes of trace metals in rats following chronic manganese chloride exposure.
Journal of Toxicology and Environmental Health Part A, 65(3-4):305–316.
Cordova, F. M., Aguiar, A. S., Peres, T. V., Lopes, M. W., Gonçalves, F. M., Pedro,
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Renton, A. E., Chiò, A., and Traynor, B. J. (2014). State of play in amyotrophic lateral
sclerosis genetics. Nature neuroscience, 17(1):17–23.
Roos, P. M. (2017). Metals and motor neuron disease. In Biometals in Neurodegener-
ative Diseases, pages 175–193. Elsevier.
Ross, S. M. (2016). Delayed cognitive and psychiatric symptoms following methyl iodide
and manganese poisoning: Potential for misdiagnosis. Cortex, 74:427–439.
Saberi, S., Stauffer, J. E., Schulte, D. J., and Ravits, J. (2015). Neuropathology of
amyotrophic lateral sclerosis and its variants. Neurologic clinics, 33(4):855–876.
Seifan, A., Schelke, M., Obeng-Aduasare, Y., and Isaacson, R. (2015). Early life epi-
demiology of alzheimer’s disease-a critical review. Neuroepidemiology, 45(4):237–254.
Smith, M. R., Fernandes, J., Go, Y.-M., and Jones, D. P. (2017). Redox dynamics of
manganese as a mitochondrial life-death switch. Biochemical and biophysical research
communications, 482(3):388–398.
135
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